Statement by the Board of Directors of Haldex in relation to the increased public cash offer by Knorr-Bremse

BACKGROUND This statement (the “Statement”) is made by the Board of Directors (the “Board”) of Haldex Aktiebolag (“Haldex” or the “Company”) pursuant to Section II.19 of Nasdaq Stockholm’s Takeover Rules (the “Takeover Rules”). On 16 September 2016, Knorr-Bremse AG (“Knorr-Bremse”) announced an increase of the consideration under its public cash offer to Haldex’s shareholders, to transfer their shares in Haldex to Knorr-Bremse, to SEK 125.00 per Haldex share. For more information about Knorr-Bremse’s increased offer, please refer to Knorr-Bremse’s announcement of its increased offer, available at www.Knorr-BremseandHaldex.com. On 16 September 2016, ZF Friedrichshafen AG, through its wholly-owned subsidiary ZF International B.V. (“ZF”), also announced an increase of its public cash offer to Haldex’s shareholders to SEK 120.00 per Haldex share. For more information about the increased offer by ZF, please refer to ZF’s announcement of its increased offer, which is available at www.zf.com. The Chairman of Haldex, Göran Carlson, has sold his shares in Haldex, representing approximately 5.7% of the total number of shares and votes in Haldex, to ZF. Please refer to ZF’s offer announcement of 14 September 2016 for more information about this agreement. As a result of Göran Carlson having sold his shares in Haldex to ZF, Göran Carlson has not participated in the Board’s decision regarding the Statement. The Board has appointed Magnus Johansson as acting chairman for the purpose of handling the Board’s decisions in relation to the ongoing offers for Haldex. Haldex has retained Lazard as financial adviser and Mannheimer Swartling as legal adviser. THE BOARD’S EVALUATION OF THE INCREASED OFFER The Board has unanimously decided to recommend the Haldex shareholders to accept the increased offer by ZF of SEK 120.00 per Haldex share, having concluded that there is a very real and material risk that Knorr-Bremse’s offer would fail to complete after a lengthy and disruptive review process and that Knorr-Bremse has done nothing to eliminate or reduce this risk, which under Knorr-Bremse’s offer would ultimately be borne by the Haldex shareholders. For more information about the reasons for the Board’s recommendation of ZF’s offer, please refer to the Board’s statement in relation to ZF’s increased offer that was announced earlier today through a separate press release, which is available at http://corporate.haldex.com. For information about the Board’s opinion of the effects the implementation of Knorr-Bremse’s offer may have on Haldex, specifically employment, and its views on Knorr-Bremse’s strategic plans for Haldex and the effect these may be expected to have on employment and the places where Haldex conducts its business, please refer to the Board’s statement in relation to Knorr-Bremse’s offer of 5 September 2016, which is available at http://corporate.haldex.com. On this basis, the Board unanimously recommends the Haldex shareholders not to accept the increased offer by Knorr-Bremse. ___________ The Statement shall in all respects be governed by and construed in accordance with substantive Swedish law. Disputes arising from the Statement shall be settled exclusively by Swedish courts. ___________ Landskrona, 19 september 2016 Haldex Aktiebolag (publ) The Board of Directors

Statement by the Board of Haldex in relation to the increased offer by ZF of SEK 120.00 per share

BACKGROUND This statement (the “Statement”) is made by the Board of Directors (the “Board”) of Haldex Aktiebolag (“Haldex” or the “Company”) pursuant to Section II.19 of Nasdaq Stockholm’s Takeover Rules (the “Takeover Rules”). On 4 August 2016, ZF Friedrichshafen AG announced, through its wholly-owned subsidiary ZF International B.V. (“ZF”), a public cash offer to Haldex’s shareholders to transfer their shares in Haldex to ZF for a consideration of SEK 100.00 per Haldex-share. On 14 September 2016, ZF announced an increase of the consideration under its offer to SEK 110.00 per Haldex share. On 16 September 2016, ZF announced another increase of the consideration under its offer to SEK 120.00 per Haldex share. For more information about ZF’s offer and the conditions of the offer, please refer to ZF’s announcement of 16 September 2016, ZF’s announcement of 14 September 2016, and ZF’s offer document, all of which are available at www.zf.com. The Chairman of Haldex, Göran Carlson, has sold his shares in Haldex, representing approximately 5.7% of the total number of shares and votes in Haldex, to ZF. Please refer to ZF’s offer announcement of 14 September 2016 for more information about this agreement. As a result of Göran Carlson having sold his shares in Haldex to ZF, Göran Carlson has not participated in the Board’s decision regarding the Statement. The Board has appointed Magnus Johansson as acting chairman for the purpose of handling the Board’s decisions in relation to the ongoing offers for Haldex. Haldex has retained Lazard as financial adviser and Mannheimer Swartling as legal adviser. THE BOARD’S EVALUATION OF THE INCREASED OFFER The Board has previously recommended the Haldex shareholders to accept the offer by ZF, first at a level of SEK 100.00 per Haldex share, and subsequently at a level of SEK 110.00 per Haldex share. For more information about the Board’s assessment of ZF’s offer and the reasons for its recommendation, including its opinion on the effects the implementation of the offer may have on Haldex, specifically employment, and its views on ZF’s strategic plans for Haldex and the effect these may be expected to have on employment and the places where Haldex conducts its business, please refer to the Board’s statement of 4 August 2016, and the Board’s statement of 14 September 2016, both of which are available at http://corporate.haldex.com. On 16 September 2016, Knorr-Bremse announced an increase of its competing public cash offer for all shares in Haldex to SEK 125.00 per Haldex share. For more information about Knorr-Bremse’s offer, please refer to Knorr-Bremse’s offer announcement of 16 August 2016 and Knorr-Bremes’s offer announcement of 16 September 2016, both of which are available at www.Knorr-BremseandHaldex.com. Knorr-Bremse’s offer is financially superior to ZF’s offer. However, in arriving at its recommendation the Board has taken into account the ability to deliver attractive value with certainty to the shareholders. ZF has announced that it has received all necessary regulatory approvals and clearances, whereas there is a very real and material risk that Knorr-Bremse’s offer would fail to complete, after a lengthy and disruptive review process, taking into account, amongst other things, that Haldex conducts significant business in both the Truck and Trailer segments. Knorr-Bremse has done nothing to eliminate or reduce this risk. Knorr-Bremse has only stated that it is fully convinced that it will successfully complete the transaction, yet its offer entails that the Haldex shareholders will bear the ultimate risk since the completion of the offer is subject to Knorr-Bremse receiving all necessary regulatory approvals and clearances on terms that are acceptable to Knorr-Bremse. Furthermore, the offer does not include any commitments by Knorr-Bremse related to the regulatory process. Accordingly, the Board has decided to reaffirm its recommendation of the ZF offer, which delivers attractive value in the form of immediate upfront cash without any regulatory risk. Based on the above, the Board unanimously recommends the Haldex shareholders to accept the increased offer by ZF. ___________ The Statement shall in all respects be governed by and construed in accordance with substantive Swedish law. Disputes arising from the Statement shall be settled exclusively by Swedish courts. ___________ Landskrona, 19 september 2016 Haldex Aktiebolag (publ) The Board of Directors 

Idogen reports positive results for follow-up products in collaboration with the University of Oxford and strengthens the portfolio

In June 2016, Idogen initiated a collaboration with Richard Williams’ research group at the Kennedy Institute of Rheumatology, University of Oxford. Richard Williams had previously carried out a successful study that showed a prolonged beneficial effect of Zebularine-treatment in a model of rheumatoid arthritis. The same study model has now been used to examine the treatment effect of potential follow-up molecules. The study shows that two of the candidate drugs significantly reduce the clinical symptoms of rheumatoid arthritis. The treatment effect also persists for a period of time after cessation of treatment. In addition, follow-up test tube experiments indicate that these molecules, like Zebularine, support the tolerogenic loop that is important for a long-lasting effect, which further strengthens the results. ”The study shows that two of the follow-up molecules to Zebularine we have tested so far have a good treatment effect in a model of rheumatoid arthritis, which is very pleasing. This study confirms that we have interesting alternative candidates for new indications. The results strengthen the company’s platform and create important opportunities in the future to out-license projects in several indications”, CEO Lars Hedbys commented. For additional information, please contact: Lars Hedbys, CEO Tel: +46 (0)46-275 63 30 E-mail: lars.hedbys@idogen.com This is an English version of an original Swedish press release communicated by Idogen AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply. This constitutes information that Idogen AB is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on the 19th of September 2016.

SCC to deliver new software development services across Europe in Preferred Partner arrangement with FPT Software

SCC, Europe’s principal independent IT services business, has signed a Preferred Partner framework agreement with Vietnamese software giant FPT Software to deliver new software services across Europe. The agreement follows SCC’s announcement in June 2016 of its expansion into Vietnam, as SCC continues its journey towards a stronger mix of annuity-based services. SCC Vietnam, headquartered in Ho Chi Minh City, will deliver two main activities: firstly, providing level three & four infrastructure support to customers, and the creation of an Offshore Development Centre to accelerate the development of internal custom applications. FPT Software, with the leading position in the Vietnamese and other markets, was chosen for its technical capability, skilled people and talented, experienced leadership team. SCC does not currently offer software development services, but the agreement sees SCC gain exclusive access to FPT Software Application Development Management Services in the UK, France, and Spain in the scope of SCC’s existing customers during the term of the agreement, adding this capability as well as additional software development capability across a number of its existing IT services – primarily Flex Resourcing and SharePoint solutions. SCC will also have exclusive access to FPT Software’s Cloud Migration service, including migration to Office 365. On the Preferred Partner basis, SCC and FPT Software also intend to jointly pursue non-exclusive projects in these regions for further portfolio services, including legacy migration, testing, infra services, mobility and analytics, representing a substantial European expansion for the Vietnamese business. SCC Chief Executive James Rigby said:  “The agreement with FPT Software represents a key milestone both in SCC’s continued transition as an IT services and solutions-led company and in the development of SCC Vietnam. We’ve been in discussions with FPT Software since arriving in Vietnam, and this is an important announcement as we gain an accomplished and capable partner. It was our intention to find a long-term partner as we introduce new software development services across each of our strategic regions, and in a business of FPT Software’s size, scale and experience, we’re now well-placed for mutual success.” Malay Verma, President of FPT USA Corp., FPT Corporation’s American business, added: “This is indeed a milestone to lay a foundation of FPT Software’s long-term partnership with SCC. The benefits to both FPT Software and SCC are clear, and extend to the customers of both businesses as SCC add new capability and we expand our footprint further into Europe. We look forward to an enduring and prosperous relationship with SCC.”

Notice of voluntary redemption

Millicom International Cellular S.A. (the "Company") hereby gives notice to all holders of the Company's 5.125% Senior Unsecured Fixed Rate Notes due 2017 (ISIN SE0004809655) (the "Fixed Rate Notes") and its STIBOR +3.500% Senior Unsecured Floating Rate Notes due 2017 (ISIN SE0004809663) (the "Floating Rate Notes", and together with the Fixed Rate Notes, the "Notes") of exercise of its option for voluntary redemption of the Notes in full, in accordance with clause 9.3 of the Terms and Conditions for the Notes. Unless otherwise defined in this notice, all words and expressions defined in the Terms and Conditions for the Notes shall have the same meaning in this notice. The Notes will be redeemed on 24 October 2016 (the "Redemption Date"). The total outstanding principal amount of the Fixed Rate Notes is SEK 64,000,000 and the total outstanding principal amount of the Floating Rate Notes is SEK 252,000,000.  The Notes will be redeemed at an amount per Note equal to the sum of: (a)        100.00 per cent. of the Nominal Amount; and (b)        accrued but unpaid Interest; and (c)        the Applicable Premium; such sum, the "Make Whole Amount". The Make Whole Amount per each Fixed Rate Note amounts to approximately SEK 1,054,742 plus accrued but unpaid interests and the Make Whole Amount per Floating Rate Note amounts to SEK 1,032,585, plus accrued but unpaid interests in each case based on the Swedish Government Bond Rate with maturity 12 August 2017. The Record Date of the redemption is 17 October 2016. The Make Whole Amount will be paid to the Noteholders on the Redemption Date. In conjunction with the redemption, the Notes will be delisted from the corporate bond list at Nasdaq Stockholm. This notice is irrevocable and is governed by Swedish law. This notice is, for the avoidance of doubt, not an offer to purchase or sell financial instruments. Millicom International Cellular S.A.

Volvo sells electric buses to Luxembourg

Sales-Lentz, one of the largest public transport operators in Luxemburg, is a forerunner in the introduction of alternative drive technologies. It was the first company to buy Volvo Hybrids in Europe as early as in 2009. Today, they have 24 Volvo hybrids and 12 Volvo electric hybrids in their fleet. Sales-Lentz now takes the next step in electrification with the purchase of four Volvo 7900 Electric buses. The buses will operate in the city of Differdange in south-western Luxembourg.The buses are sold as a turn-key solution. Volvo will be responsible for vehicle servicing including battery maintenance for a fixed monthly cost. Traffic start is planned for the second quarter of 2017. “With this new efficient technology developed by Volvo, Sales-Lentz promotes the ambition of the City of Differdange to build a sustainable change for the transportation of persons and improve the quality of life for citizens. Change is the parent of progress”, said Wolfgang Schroeder, Managing Director, Sales-Lentz.“Engaged for many years, we have implemented an ambitious plan to sustainably envisage our city. Called "Differdangechange", we want to rethink the effectiveness of all our actions, particularly our communal transport "Diffbus". We are proud that our City-bus can be continued in a pioneering system and participate to an exemplarity in Luxembourg, together with the stakeholders, for preserve our living city and our environment”, said Roberto Traversini, Mayor of the city of Differdange. “Electric bus systems is a cost-efficient solution for cities to reduce the problems of poor air quality and noise. Emission-free, silent buses also open up entirely new possibilities for urban planning”, said Håkan Agnevall, President Volvo Buses. The buses will be charged with opportunity charging (fast charging at end stops). To facilitate the introduction of electric bus systems in European cities, Volvo together with several other manufacturers of buses and infrastructure agreed this spring to an open interface between electric buses and charging infrastructure. The system includes automatic contacting by a pantograph, wireless communication, contacting plates and infrastructure equipment that automatically contact vehicles with a pantograph. Volvo 7900 Electric ·  All-electric two-axle 12-metre long city bus with low floor and three doors. ·  80 % lower energy consumption than a corresponding diesel bus. ·  Quiet, emission-free operation. ·  Equipped with an electric motor and lithium ion batteries. ·  The batteries can be charged at the end stops in three to six minutes.   ·  Bright and airy interior. ·  85 passengers. *Recharging time depends on topography, load and climate conditions. OppCharge ·  Open interface between charging station and vehicle  ·  Offering charging power of 150 kW or 300 kW   ·  Charging takes 3-6 minutes  ·  Inverted pantograph enables use of a low-cost and low weight interface on roof of the bus ·  Conductive static charging with pantograph where communication between bus and charging station is done via WiFi

EQT Mid Market to acquire XP Solutions

· EQT Mid Market agrees to acquire XP Solutions, a US-based global leading provider of water infrastructure and flood control software for engineers, regulators, and water authorities, from Cardno · EQT Mid Market is committed to supporting continued growth and expansion of the Company, through organic and acquisitive growth The EQT Mid Market Investment strategy (“EQT Mid Market”) has agreed to acquire XP Solutions (“XP Solutions” or the “Company”) from Cardno (“Cardno”), an ASX-listed professional infrastructure and environmental services company based in Australia. The management team of XP Solutions, led by Colby Manwaring, will remain with the Company and continue to lead its growth. Financial terms of the transaction were not disclosed. Founded in 1974, the Company provides water infrastructure and flood control software solutions to engineers, regulators, and water authorities. XP Solutions is known for its deep domain knowledge and technical expertise through 40 years of industry experience. Its solutions are uniquely embedded with regulatory standard functionality and the offerings range from hydraulics analysis software for drainage infrastructure design, storm/flood modeling, and visualization. The Company is headquartered in the US and has over 60 employees in North America, Europe, Australia, and Asia. EQT Mid Market is keen to support the continued growth of XP Solutions both domestically and internationally. Particular focus will be on developing the Company’s North American sales function, introducing new products, and expanding the Company’s footprint through acquisitions. Matt Levine, Partner at EQT Partners, Investment Advisor to EQT Mid Market, says:“We are impressed with XP Solutions’ unique product offerings and market leadership position in key segments and regions. Colby and his team have built an excellent technology platform that has grown consistently over time. EQT’s strong expertise in the software and infrastructure sectors, alongside EQT’s global network, will be great support in the company´s international expansion.” Colby Manwaring, President of XP Solutions, says:“XP Solutions is pleased to join with EQT as we pursue the next phase of growth for the company. We are looking forward to continuing to work within a support structure that will allow us to broaden our software range and reach more clients globally. EQT shares our vision of building XP Solutions as a world leading provider of software solutions for infrastructure and environmental professionals.” Contacts:Kerstin Danasten, EQT Press Officer, +46 8 506 55 334Matt Levine, Partner at EQT Partners, Investment Advisor to EQT Mid Market, +1-917-281-0849 About EQTEQT is a leading private equity group in Europe with approximately EUR 30 billion in raised capital. EQT funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 15 billion and approximately 100,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership. For further information, please visit www.eqtpartners.com About XP SolutionsEstablished in 1974, XP Solutions is a world leading provider of industry standard sustainable drainage and flood hazard software for the civil engineering and environmental sectors. The software technology and professional solutions are used globally by government agencies, engineering companies and environmental management organizations to plan, design, simulate and manage the impact of human interaction with the natural world. XP Solutions is headquartered in Portland, Oregon. For further information, please visit www.xpsolutions.com

Optimarin USCG type approval imminent as DNV GL submits documentation

Press Release - for immediate release 19 September 2016, Norway: Ballast water treatment (BWT) specialist Optimarin is on the brink of becoming the first supplier of an environmentally friendly UV-based system to gain USCG approval. The Norwegian firm, which has focused exclusively on BWT since its formation in 1994, has satisfied the coast guard’s stringent testing criteria for fresh, brackish and marine water. DNV GL has now submitted all final documentation on Optimarin’s behalf, with full approval expected in Q4 2016. The news follows on the heels of the long-awaited ratification of the IMO Ballast Water Management (BWM) Convention, with Finland’s signature pushing it past the 35% of combined global tonnage (from at least 30 contracting states) needed to bring it into force. Optimarin CEO Tore Andersen believes this dual development will “turbo charge” a business already sitting at the vanguard of the market. “This has been Optimarin’s best year in business,” he states. “On the back of our success with USCG testing we’ve seen orders steadily build, with contracts signed for over 100 of our Optimarin Ballast Systems (OBS) so far. “The ratification is, of course, wonderful news, but it’s the USCG approval that arguably provides our key point of difference.” He explains: “USCG standards are more stringent than those of IMO and all vessels discharging ballast water in the US waters will be forced to fit systems that comply with their demanding CMFDA standard. This ensures the elimination of all potentially invasive species. “For shipowners with global fleets and a need for flexibility, the ability to operate in US waters is a must. So, for them, having a compliant system is a ticket to trade. Our established technology delivers just that, while our installation and retrofit expertise provides complete peace of mind. We believe we’re now the clear choice for our segments.” Optimarin has currently received orders for around 500 of its market proven systems, which utilise a combination of filtration and powerful 35kW UV lamps to treat ballast water without the need for chemicals. Of these units 280 have been installed worldwide, with close to 100 retrofits, fitted in tandem with global engineering partners Goltens and Zeppelin. Recent orders include ten units for Atlantis Tankers, 15 systems for Vard Group, three for Saga Shipholding (adding to an additional 26 systems already installed on its fleet), two for Solvang ASA, and a frame agreement with Carisbrooke with the potential to encompass retrofits on 46 bulk and multipurpose vessels. Sales for the year are up by close to 200%. “The years of investment, experience and a dedicated focus on BWT are now paying off,” Andersen concludes. “The business feels like it’s been turbo-charged. With proven, simple, flexible and reliable technology, that meets all present and future regulatory requirements, we can offer shipowners exactly what they need to satisfy individual vessel needs. “On the back of the BWM ratification, and our imminent USCG approval, that puts Optimarin in an excellent position for long-term dependability and success.” Optimarin’s USCG testing was conducted by DNV GL at the NIVA test facility in Norway, and on seaboard tests, with the pumps on the Optimarin Ballast System (OBS) running at full treatment rated capacity. As well as satisfying all IMO and USCG requirements, OBS is certified by a comprehensive range of classification organisations, including DNV GL, Lloyd’s, Bureau Veritas, MLIT Japan, and American Bureau of Shipping. For further information please contact: Optimarin:Tore AndersenOptimarin CEOTel: + +47 911 35 860Email: tandersen@optimarin.comwww.optimarin.com

Sivers IMA finalizes 10 Gbps EU project

Within the E3network project, a prototype of a very high‐speed (10 Gbps) E‐band point‐to‐point link was designed, manufactured, and evaluated together with several partners. This kind of mm‐wave data links covering 71 – 76 and 81 – 86 GHz are crucial for future telecommunication systems supporting high‐speed data to the user. “This project shows Sivers IMA's capabilities to work with many of the best organizations in Europe in order to create a high‐speed point‐to‐point link prototype with very competitive performance”, says Anders Storm, CEO of Sivers IMA. It has been a very ambitious project which began with a comprehensive system analysis in order to derive the specification necessary for this mm‐wave link. The critical hardware was then identified and designed within the project. This included transmit/receive baseband functions implemented in FPGAs and RF front‐end circuits using an advanced BiCMOS process. These key hardware parts were combined with commercial blocks to form a complete mm‐wave point‐to‐point link. In parallel with the design work, the project has also been active in the European Telecommunications Standards Institute (ETSI) defining the future usage of E‐band in Europe. As a result, the E3network Radio Profile has been accepted as the candidate for the new ETSI 10 Gbps / 2 GHz profile. The E3network consortium consisted of: CEIT (Spain – coordinator), Fraunhofer (Germany), ALCATEL‐LUCENT (nowadays NOKIA – Italy), CEA (France), INCIDE (nowadays IXYS – Spain), Silicon Radar (Germany), ST Microelectronics (Italy), Sivers IMA (Sweden), and OTE (Greece). For questions, please contact:Anders Storm, CEO Sivers IMA, +46 70 262 6390 Sivers IMA is a leading manufacturer of micro‐ and millimeter wave products for connecting and quantifying anetworked world. Sivers IMA has a long history and is internationally renowned as a reliable supplier of high quality components used in telecommunications links, RADAR sensors and test & measurement equipment. Headquarters is located north of Stockholm in Kista, Sweden. Learn more at http://siversima.com. 

Hadley Park House Hotel receives 4-star status after £100K refurbishment

The family-owned 22-bedroom hotel which employs 40 staff has recently invested in a £100,000 refurbishment programme. The project focused on all 12 bedrooms in the original Georgian house which were completely redecorated and new carpets, lighting, hard and soft furnishings installed. The hotel’s conservatory restaurant, adjacent bar, Morning Room and Lounge have also had a makeover with redecoration, new lighting and the extensive wood flooring taken back to reveal the original floorboards. New carpets have been laid in the hotel’s entrance and reception area.   The refurbishment has been designed to ensure the hotel seamlessly caters for both business, leisure and wedding guests alike, providing both residents and non-residents with the highest level of comfort and style.   Mark Lewis and Geraldine Lewis, owners of Hadley Park House Hotel said the four-star accolade was a tribute to their employees as well as recognition of improved quality standards throughout the hotel. “Hadley Park House Hotel is in a unique position in that we are a family business and we work hard to maintain exceptional quality and standards. As well as our strong links and commitment to the local community and local charities, the business is central to the bigger tourism picture providing Shropshire with a quality hotel which attracts both business and leisure travellers. The four-star status provides our unique hotel a distinct point of difference, and this continues to be an exciting time for the hotel and we would love local people to pop in and see the changes.”   Hadley Park House Hotel has been twice voted Best Town Wedding Venue in the West Midlands at the Wedding Industry Awards in 2015 and 2016. The hotel also has 1 AA Rosette for food quality. ENDS

Nominating committee appointed at NetEnt AB (publ) ahead of AGM 2017

In accordance with the decision by the Annual General Meeting, the members of the nominating committee of NetEnt should be appointed by the three shareholders/owner groups controlling the largest number of votes in NetEnt at the end of August, which desire to appoint a representative. In addition, the Chairman of the Board of Directors shall be a member of the nominating Committee. NetEnt hereby announces that the nominating committee has now been appointed ahead of the Annual General Meeting in April 2017, and consists of the following members: • John Wattin, Chairman (appointed by the Hamberg family)• Christoffer Lundström (appointed by Provobis Property & Leisure AB)• Fredrik Carlsson (appointed by the Knutsson family)• Vigo Carlund (Chairman of the Board of Directors) Shareholders can submit proposals to the nominating committee until December 2nd 2016 at: Nominating Committee, NetEnt AB, Luntmakargatan 18, SE-111 37 Stockholm, Sweden or to nomination@netent.com. The Annual General Meeting will be held in Stockholm on April 21, 2017. For additional information please contact:Maria Hedengren, CFO, NetEnt AB (publ)Phone +46 8 57 85 45 00maria.hedengren@netent.com Roland Glasfors, Investor Relations, NetEnt AB (publ)Phone: +46 760 024 863roland.glasfors@netent.com This information is information that NetEnt AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 11:00 CET on September 19, 2016. About NetEntNetEnt AB (publ) is a leading digital entertainment company, providing premium gaming solutions to the world’s most successful online casino operators. Since its inception in 1996, NetEnt has been a true pioneer in driving the market with thrilling games powered by a cutting-edge platform. NetEnt is committed to helping customers stay ahead of the competition, is listed on NASDAQ Stockholm (NET–B) and employs 800 people in Stockholm, Malta, Kiev, Krakow, Gothenburg, Gibraltar and New Jersey. www.netent.com

Temporary change of Chairman of the Board in Viking Supply Ships

Giving reference to the press release of 15 September where it is announced that Mr. Bengt A. Rem is appointed as interim CEO of Viking Supply Ships. The board has decided that Mr. Folke Patriksson will take over the duties as Chairman of the Board for as long as Mr. Bengt A. Rem is interim CEO. Bengt A. Rem will continue in the board as board member. Mr. Folke Patriksson (b. 1940) has significant experience within the shipping industry and is one of the founders of Viking Supply Ships AB and former managing director of the company. Mr. Folke Patriksson is currently deputy Chairman of the Board and has been a member of the Board since 1972. For further information, please contact:   Bengt A. Rem, Interim CEO, ph. +47 94 01 71 71, e-mail bengt.rem@kistefos.no  Morten G. Aggvin, IR & Treasury Director, ph. +47 41 04 71 25, e-mail mga@vikingsupply.com  Viking Supply Ships AB (publ) is a Swedish company with headquarter in Gothenburg, Sweden. Viking Supply Ships A/S is a subsidiary of Viking Supply Ships AB (publ). In addition Viking Supply Ships AB (publ) has the subsidiary TransAtlantic AB. The operations are focused on offshore and icebreaking primarily in Arctic and subarctic areas as well as on Shipping services mainly between the Baltic Sea and the Continent. The company has in total about 500 employees and the turnover in 2015 was MSEK 1,977. The company’s B-shares are listed on the NASDAQ Stockholm, Small Cap segment. For further information, please visit: www.vikingsupply.com  This information is information that Viking Supply Ships AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 12:00 CET on 19 September 2016. 

illuminating York – top festival of light returns to the historic city this October

Transforming aspects of the city through the use of light – that’s the promise from organisers of the eleventh illuminating York, supported by Arts Council England, which returns to the city from Wednesday 26 to Saturday 29 October 2016.  This year’s event features seven newly commissioned artworks using light, an expanded light trail and a host of ‘fringe’ events to create evenings to remember across York’s historic streets. This year’s festival will see new venues host specially commissioned artworks, with outdoor installations highlighting some of York’s most intriguing buildings and spaces, and indoor illumination using projection, colour and light to showcase very different aspects of York’s heritage, from the industrial past of National Railway Museum’s workshops to the interior of Holy Trinity Church in Goodramgate.  Internationally-renowned artists such as Jason Bruges Studio, Heinrich and Palmer, Helen Maurer and Studio PSK will contribute new artworks to this year’s event. “This year’s illuminating York has been developed to take visitors on an exploration of the city after dark, with key venues hosting our newly commissioned artworks, three architectural lighting schemes around the city in partnership with the Society of Light and Lighting, and illuminated bunnies in 50 shop and business windows throughout the city centre in our own trail,” comments one of illuminating York’s curators, Hazel Colquhoun.  “We’re being joined in the ‘fringe events’ this year by other venues opening late on specific nights with illumination-themed events and activities, from Fairfax House and The Bar Convent Living Heritage Centre to night time opening of the City Walls so that people can return for two or more nights for a different illuminating York experience.” Eight key highlights in this year’s illuminating York will be: York Minster – Jason Bruges Studio After a triumph lighting The Shard in London on New Year’s Eve, Jason Bruges Studio will become ‘light masons’ within the cavernous nave of York’s gothic cathedral.  Using only white light and particulate suspended in the air, visitors will experience spectacular choreographed spaces carved out of light.  This is the only paid-for commission, with standard admission prices of £8 for adults and £3.50 for children, which also includes admission to the East End exhibition and Chapter House.  Each ticket is allocated a time slot and family ticket deals are available.  Tickets are available from York Theatre Royal and York Minster box offices.  Early bird discounts are also available until 9 October, priced at £6 and £3.  Family tickets are also available. York St John University – David Ogle’s ‘Lumen’ A new venue for illuminating York, the historic quad at York St John’s Lord Mayor’s Walk campus will be occupied by a forest of light.  Visitors can walk amongst skeletal coloured luminescent trees, to experience the unusual light and shade cast by their glowing branches, with further exhibitions and performances by York St John Students to discover around the campus.  Free. National Railway Museum (NRM) – Heinrich and Palmer Pioneers of large-scale illuminated art, Heinrich and Palmer turn their attention to the Workshop at NRM, creating an experience that brings together projection, light drawings, film and sound in the working heart of the museum, where engines are maintained and restored.  Visitors will also see the return of Locos in a Different Light, at the NRM, where the halls and locomotives are transformed with colour and light by theatre lighting design students.  Free.  Holy Trinity Church, Goodramgate – Helen Maurer Secrets in the stained glass inspire the displays inside this historic building as Helen Maurer creates a compelling installation using light, glass and mirrors to project shape and colour onto the walls and ceiling.  Free. Shambles – ‘Orbit’ by Studio PSK Regularly voted one of Britain’s most picturesque streets, Studio PSK has designed ‘Orbit’ which will be installed along the entire length of the world-famous Shambles.  Arcs of light will revolve above the heads of the visitors encircling views of the iconic street, prompting them to look up from the historic street. Free. King’s Square – ‘Loopy Lou’ by Rémi Brun “Loupy Lou” presents a skipping figure, whose movements are created by just a few LED lights. In daylight, Brun’s sculpture looks like an abstract wire construction, but after dark, the LED lights that dance around create a depiction of a skipping girl, based on the artist’s daughter playing. Remi Brun lives and works in Paris and this is the first time his work has been shown in a UK light festival. Free. Society of Light & Lighting Projects – various locations The Society of Light & Lighting– the top industry body for those working in the lighting sector – will be working with schools around York to create lighting schemes for three venues, including parts of the city walls and St Michael-le-Belfry.  Free. Bunny Light Trail – various locations between the major installations Making a return after its debut last year will be the popular Bunny Light Trail, in collaboration with York contemporary design store Snow Home, where 50 bunny lights customised by artists and creatives will be placed in shop and business windows across the city centre. Adding to the main programme will be a packed festival Fringe programme with venues across the city taking part, from candlelit tours of Fairfax House to Gregorian Latin Chant with ‘Illuminations by Visions of York’ in All Saints North Street Church. Kate McMullen, Head of Tourism, Make It York, said, “illuminating York is unlike any other light festival.  What’s unique about York’s festival is that the artists have spent time in the city and the different venues to create artworks that are designed specifically around these individual and historic York locations.” “Exhibits from previous years have gone on to win awards when they are displayed in other venues around the world, so this is a chance to see the premier of these stunning works in the location that inspired their creation.  illuminating York is one of the reasons York was able to secure the coveted UNESCO City of Media Arts status – and other cities turn to York for inspiration.” illuminating York is managed by Make It York on behalf of a city-wide steering group, chaired by Liz Page, Historic Properties Director (North) - English Heritage.  For more information, please visitilluminatingyork.org.uk ENDS Notes to editors: · The festival gains over 50,000 ‘visits’ every year · Over the past ten years the festival has commissioned over fifty artworks for the city · illuminating York is a member of ‘Light Up the North’, a network of seven light festivals taking place in cities across the North of England www.lightupthenorth.com · illuminating York was named by The Guardian in its top ten European Lighting Festivals · In 2015 the illuminating York Festival was nominated for a Dulux Colour Award · illuminating York is managed by Make It York on behalf of a city-wide steering group, chaired by Liz Page, Historic Properties Director (North) - English Heritage · The principal funder of the festival is Arts Council England, with additional funding from ticketing and private sponsors · illuminating York is organised by Make It York supported by Arts Council England.  This year’s partners include English Heritage, National Railway Museum, The Society of Lighting and Light, York Minster and York St John University. Make It York (York’s Destination Organisation) – Make It York’s purpose is to develop and promote the city and its surroundings – nationally and internationally - as a vibrant and attractive place to live, visit, study, work and do business.  Visit York is a part of Make It York and is the leisure tourism brand Under the brand Visit York, Make It York’s aim is to market York as a must-see world-class destination to the leisure visitor and ensure investment to develop the quality of tourism in York. Key tourism facts: 6.8 million visitors annually, £608 million total visitor spend, supporting 23,300 jobs. For further media information, interviews or photographs, please contact: Jay Commins, Samantha Orange or Nicola Bexon Pyper York Limited On Behalf of Make It York: Tel:         01904 500698 Email:    jay@pyperyork.co.uk, sam@pyperyork.co.uk or nicola@pyperyork.co.uk

Millicom appoints Rodrigo Diehl as Executive Vice President, Chief Strategy Officer

Rodrigo Diehl is joining Millicom as part of the company’s drive to constantly improve its strategic rigour and maintain its competitive advantages in a rapidly transforming industry. Diehl will report to Chief Executive Officer, Mauricio Ramos. Diehl brings a wealth of experience in the evolution of the telecommunications and technology sectors, and an in-depth understanding of the Latin American region, from his previous roles. Before joining Millicom, Diehl worked as a Partner at McKinsey & Co. both in Germany and in Brazil where, since 2003, he advised telecommunications, technology and media leaders throughout Europe, the USA, Middle East and Latin America. As a leader of McKinsey’s Telecom, Media and Technology Practice in Latin America, he has worked closely with telecom operators, IT service providers, software players and device manufacturers across diverse functions including strategy, operations and sales and marketing. Prior to joining McKinsey, he worked as a Senior Analyst and Planning Manager at Techint Group Throughout his career, Diehl has helped governments define their vision and aspirations for the telecom and technology sectors, and published on trends and best practices in the industry. In this regard, he has authored several industry reports on behalf of McKinsey & Co. Rodrigo was also a leader at Digital McKinsey, helping companies stay ahead of emerging digital technology and harnessing its power to shape new business models. He graduated with honours from the University of Buenos Aires and holds an MBA from Harvard Business School. Rodrigo speaks fluent English, Portuguese, Spanish and German. Commenting on the new appointment, Chief Executive Officer Mauricio Ramos said: “I am delighted to welcome Rodrigo Diehl to Millicom. With his strengths and experience across the telecoms and technology ecosystem in Latin America in particular, Rodrigo will be able to help us to further hone our strategy as we continue to drive growth across the business.” Rodrigo Diehl added: “This is a transformational time for the digital and telecommunications space, and Millicom is well positioned in its markets to harness the converging power of mobile data, high-speed broadband and video for the benefit of its customers, business clients and also the wider community. I'm thrilled to be joining a business with extremely high potential and I look forward to supporting Millicom as it takes The Digital Lifestyle further.”

ASCO, ASTRO and SSO update guideline on postmastectomy radiotherapy

ALEXANDRIA, Va, ARLINGTON, Va, ROSEMONT, Ill. — Three leading national cancer organizations today issued a joint clinical practice guideline update for physicians treating women with breast cancer who have undergone a mastectomy. The update provides additional considerations for physicians to determine which patients might benefit from postmastectomy radiotherapy (PMRT). “We still don’t have a single, validated formula that can determine who needs PMRT, but we hope that the research evidence summarized in this guideline update will help doctors and patients make more informed decisions,” said Stephen B. Edge, MD, co-chair of the Expert Panel that developed the guideline update. “We also hope that this publication will spur more research into patient and tumor characteristics that predict risk of recurrence after mastectomy.” The American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO) and the Society of Surgical Oncology (SSO) together published the new guideline update in their respective journals, the Journal of Clinical Oncology, Practical Radiation Oncology and Annals of Surgical Oncology.  “In an era of personalized medicine, we want to be sure that we offer the right care to the right patients. Thanks to advances in systemic therapy, fewer women need radiation therapy after a mastectomy,” said Abram Recht, MD, co-chair of the Expert Panel that developed the guideline update. “This means we can be more selective when recommending this treatment to our patients.” The guideline update states that there is strong evidence showing that PMRT reduces the risk of breast cancer recurrence.  It provides evidence-based recommendations for the use of postmastectomy radiotherapy in: patients with T1-2 tumors (tumors smaller than 5 cm) and 1 to 3 positive lymph nodes; patients undergoing neoadjuvant systemic therapy (NAST); and patients with T1-2 tumors and a positive sentinel node biopsy.  The Expert Panel also addressed technical aspects of radiotherapy, such as the optimal extent of regional nodal irradiation (RNI). “For many women, PMRT reduces the risk of local and regional failure, but physicians must weigh this benefit with the considerable side effects associated with this treatment,” said Bruce G. Haffty, MD, immediate past chair of ASTRO’s Board of Directors. “This cooperative guideline underscores the complexity inherent in decisions related to PMRT, as well as the importance of clinical judgment in treatment planning.” To develop this guideline update, an Expert Panel reviewed relevant literature published between January 2001 and July 2015. This included a meta-analysis of 22 clinical trials published in 2014, which provides evidence that PMRT is highly effective at preventing local breast cancer recurrence.   Key recommendations of the guideline update are as follows: ·Decision to use PMRT should involve providers from all treating disciplines as well as the patient. Doctors and patients should discuss risks and benefits to determine the best treatment approach for the patient. ·For women with T1-2 breast cancer and 1-3 positive lymph nodes, PMRT reduces the risk of recurrence and breast cancer death. However, for some patients with a low risk of recurrence, the potential complications of PMRT may outweigh the benefit. ·When making decisions on recommending PMRT, doctors should consider patient and tumor characteristics that may diminish the benefit of PMRT or increase the risk of complications. ·Patients with T1-2 tumors with a positive sentinel node biopsy who elect to omit axillary lymph node dissection should receive PMRT only if there is already sufficient information to justify its use without needing to know that additional axillary nodes are involved. ·Patients with axillary nodal involvement that persists following neoadjuvant systemic therapy should receive PMRT. ·Radiation should generally be given to both the internal mammary nodes and the supraclavicular-axillary apical nodes in addition to the chest wall or reconstructed breast when PMRT is used for patients with positive axillary lymph nodes. “This guideline highlights the need to individualize therapy as well as identifies areas where more research is needed,” said Monica Morrow, MD, FACS, the SSO representative on the Expert Panel that developed the guideline update. “It emphasizes that we are moving beyond a simplistic one size fits all approach to more tailored therapy which will improve benefits for patients.” View the complete guideline in the following journals: ·Annals of Surgical Oncology (http://link.springer.com/10.1245/s10434-016-5558-8) ·Practical Radiation Oncology (http://www.practicalradonc.org/article/S1879-8500(16)30159-X/fulltext) · Journal of Clinical Oncology (http://drives.asco.org/commpi/CommPi%20T%20Drive/QUALITY/GUIDELINES/2016/Postmastectomy%20Radiotherapy%20Update/Press%20Release/jco.ascopubs.org/lookup/doi/10.1200/JCO.2016.69.1188) Media Contacts · ASCO: Amanda Narod (amanda.narod@asco.org), 571-483-1795 · ASTRO: Liz Gardner (liz.gardner@astro.org), 703-286-1600 · SSO: Chris Martin (cmartin@davidjamesgroup.com), 630-670-2745 ABOUT ASCO Founded in 1964, the American Society of Clinical Oncology (ASCO) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook (https://www.facebook.com/ASCOCancer), Twitter (https://twitter.com/ASCO), LinkedIn (https://www.linkedin.com/groups/93067), and YouTube (https://www.youtube.com/user/ASCOcancer). ABOUT ASTRO ASTRO is the premier radiation oncology society in the world, with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, the Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes three medical journals, International Journal of Radiation Oncology • Biology • Physics (www.redjournal.org), Practical Radiation Oncology (www.practicalradonc.org) and Advances in Radiation Oncology (www.advancesradonc.org); developed and maintains an extensive patient website, RT Answers (www.rtanswers.org); and created the Radiation Oncology Institute (www.roinstitute.org), a nonprofit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment. To learn more about ASTRO, visit www.astro.org. ABOUT SSO The Society of Surgical Oncology (SSO) is the premier organization for surgeons and health care providers dedicated to advancing and promoting the science and treatment of cancer. The Society’s focus on all solid-tumor disease sites is reflected in its Annual Cancer Symposium, monthly scientific journal (Annals of Surgical Oncology), educational initiatives and committee structure. The Society’s mission is to improve multidisciplinary patient care by advancing the science, education and practice of cancer surgery worldwide.

Installation initiated for Elekta’s high-field MR-adaptive linear accelerator at Froedtert & the Medical College of Wisconsin Clinical Cancer Center

MILWAUKEE, September 20, 2016 – Elekta (EKTA-B.ST), its MRI technology partner Royal Philips (NYSE: PHG, AEX: PHIA) and the Froedtert & the Medical College of Wisconsin Cancer Network recently began installation of an investigational high-field MR-adaptive linear accelerator (MR-linac) system at the Froedtert & MCW Clinical Cancer Center at Froedtert Hospital, eastern Wisconsin’s only academic medical center. The Clinical Cancer Center, part of the Froedtert & MCW Cancer Network, is the second U.S. and fifth global site to install the MR-linac system, which is already under functional evaluation at The Netherlands Cancer Institute; University Medical Center Utrecht, the Netherlands; The University of Texas MD Anderson Cancer Center, Houston Texas; and the Institute of Cancer Research, working with its clinical partner The Royal Marsden NHS Foundation Trust in London. In 2013, the Froedtert & MCW Cancer Network joined Elekta’s MR-linac research consortium, a global collaboration of institutions focused on uniting leaders in radiation oncology, MR-imaging and physics. The mission of the consortium is to investigate that MR-linac technology can lead to improved patient outcomes for existing radiation therapy indications and extend radiation therapy for additional indications. “For more than a decade, the Froedtert & MCW Cancer Network has been at the forefront of the evolution of radiation therapy with the goal of providing more personalized treatments,” said Christopher Schultz, MD, FACR, Professor and Chairman of the Department of Radiation Oncology, at the Froedtert & MCW Cancer Network. “The foundational work we’ve been doing with MRI-based treatment planning strongly positions us to be among the experts invited to help develop this latest milestone in treating cancer.” Elekta’s MR-linac integrates, for the first time, an ultramodern radiotherapy system and a high-field MRI scanner with novel software. It enables a physician to capture diagnostic quality images of tumors and surrounding tissues during radiation therapy delivery. The MR-linac is designed to improve targeting of tumor tissue while reducing exposure of healthy tissue to radiation. It could allow physicians to precisely target a tumor and lock onto it during treatment, even when tumor tissue is moving during treatment or changes shape, location, size or composition between treatment sessions. Elekta and its global collaborators overcame significant engineering hurdles to demonstrate the technology’s feasibility. Previously, experts in the field thought it nearly impossible to combine MRI and linear accelerator devices because the powerful MRI magnets could interfere with radiation beams. “While we already have significant evidence supporting the potential of MR-linac, fully realizing its practical applications will require rigorous evaluation in real world clinical settings,” said J. Frank Wilson, MD, FACR, FASTRO, radiation oncologist; Bernard and Miriam Peck Family Professor of Radiation Oncology with Froedtert & MCW Cancer Network. “Initially, we will focus on establishing clinical protocols and refining methods for data collection and analysis in pancreatic cancer, a deadly disease with limited treatment options. We are optimistic that MR-linac will be a critical advancement in patient care and ultimately, improve outcomes in this and other types of cancers.” “We appreciate the continued guidance and support from the Froedtert & MCW Cancer Network and our other consortium members, who have been instrumental in advancing the development of high-field MR-linac,” said Kevin Brown, Elekta’s Global Vice President of Scientific Research. “This installation marks the latest milestone in our rapid progress to make this technology a clinical reality, and we believe MR-linac will transform how radiotherapy is delivered and establish new standards of care for difficult to treat cancers.” "Philips is a pioneer and leader in image guided minimally invasive therapies, a fast growing field because of the benefits for patients, hospitals and health systems," said Rob Cascella, CEO Diagnosis & Treatment Businesses at Philips. “We have been expanding our efforts in interventional oncology, as we are convinced that image-guided therapies will have a positive, transformational impact on oncology. With the combined expertise of Elekta, Philips and other consortium partners such as Froedtert & the Medical College of Wisconsin Cancer Network, we are entering an exciting new phase in exploring the potential of image-guided radiotherapy as a game changer in cancer treatment.”  Consortium members are currently engaged in various stages of evaluation of the technology and are collaborating to establish new clinical protocols and develop methods for data collection and analysis. The consortium, which will gather for an annual meeting at the Clinical Cancer Center September 29-30, is evaluating how this new radiation treatment technology may improve care for patients with prominent and deadly cancers including brain, breast, cervix, esophagus, lung, oropharynx, pancreas, prostate and rectal cancers. Elekta’s MR-linac is a work in progress and not available for sale or distribution. # # # For further information, please contact:Gert van Santen, Group Vice President Corporate Communications, Elekta ABTel: +31 653 561 242, e-mail: gert.vansanten@elekta.comTime zone: CET: Central European Time Tobias Bülow, Director Financial Communication, Elekta ABTel: +46 722 215 017, email: tobias.bulow@elekta.comTime zone: CET: Central European Time Steve Klink, Philips Group CommunicationsTel: +31 610 888 824, e-mail: steve.klink@philips.comTime zone: CET: Central European Time Gerry Steele, Media Relations Associate, Froedtert & the Medical College of WisconsinTel: +1 414-805-3057, e-mail: gerry.steele@froedtert.comTime zone: CT: Central Time The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07:30 CET on September 20, 2016. About ElektaElekta (NSE:EKTAb) is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives. Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,600 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: www.elekta.com. About Royal PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. The company, headquartered in the Netherlands, is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips’ health technology portfolio generated 2015 sales of EUR 16.8 billion and employs approximately 69,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter. About Froedtert & the Medical College of Wisconsin health networkThe Froedtert & the Medical College of Wisconsin regional health network is a partnership between Froedtert Health and the Medical College of Wisconsin. It comprises eastern Wisconsin’s only academic medical center, Froedtert Hospital, Milwaukee; Community Memorial Hospital, Menomonee Falls; and St. Joseph’s Hospital, West Bend. The health network also includes more than 2,700 physicians across 25 primary and specialty clinical locations representing the collaboration of Wisconsin’s largest multispecialty physician practice with a community-based physician group. The network’s three hospitals have 804 staffed beds, more than 40,000 annual admissions and nearly 966,000 annual outpatient visits. Froedtert & MCW network physicians have more than 775,000 annual patient visits at its health centers and clinics. For information, visit froedtert.com (http://www.froedtert.com/).

Cantargia prepares intensified development strategy and capital raising

Inclusion of combination therapies in the initial clinical study of CAN04 "Cantargia’s decision to increase the level of ambition in the CAN04 project is among the most important and the most intensified in the company's history. This marks a major step to enhance the value of the CAN04 project and take greater advantage of the potential around the target IL1RAP (Interleukin 1 Receptor Associated Protein). I feel enthusiastic about the opportunities that open up with our intensified development strategy", says Göran Forsberg, CEO of Cantargia. The decision has been taken in consultation with international key opinion leaders in the field of solid tumors, and it represents a significantly increased level of ambition in the initial stage of the clinical studies of Cantargia’s product candidate CAN04 against non-small cell lung cancer (NSCLC) and pancreatic cancer. By expanding the study to include combination therapies – where CAN04 is combined with existing standard treatment – Cantargia will receive significantly more data, which allows the company to accelerate the overall development of CAN04. This improves the conditions for a partnership of CAN04. Cancer treatment today is often some form of combination treatment, and in view of the good safety and unique mechanism, CAN04 can potentially be a good substance to combine with other treatments. The clinical study protocol is still under development. It will be based on an adaptive design which means increased flexibility during the trial. The protocol will provide relevant data on combination therapy and significantly more information than initially planned. During 2017 Cantargia plans to start preclinical studies with different types of combination therapies to support the clinical development. The clinical study of CAN04 is now planned to start during the first half of 2017, and a presentation of the phase I data is planned about a year after the start of the study. More data will be generated continuously, but based on the first data set, the foundation is laid for Cantargia’s ambition to find a partner who can take responsibility for the latter stages of clinical development. When phase I data are reported, in addition to the current study, the company also intends to finalize a protocol and start a clinical phase IIa trial for leukemia. The next step in the production development of CAN04 In June 2016, Cantargia decided to invest in the further optimization of its production processes, which has resulted in a production process that can be used to produce material for initial clinical trials. Because of the company's development strategy, the production process needs, however, to be carried out in a larger scale and at a higher cost than initially planned. Therefore, as part of the more aggressive clinical development of CAN04, Cantargia plans to invest in further process development of a production method that meets the requirements in subsequent clinical studies. Like other antibody production processes, substantial development activity and process optimization are needed between early and late clinical phase in order to increase yields and ensure a robust production. Through the investment in the production process, a better opportunity to take advantage of the time savings made in the overall clinical development is created. Start of a new project against autoimmunity and inflammation Cantargia intends to initiate the development of a new antibody against IL1RAP with properties optimized for the treatment of autoimmune and inflammatory diseases. IL1RAP mediates signals of both the cytokines IL-1 and IL-33, which have a role in several severe autoimmune and inflammatory diseases. The project is planned to start in 2017, and the goal is to select a clinical candidate that can enter development at the end of 2018 or the beginning of 2019. By starting a new project against a disease segment that complements CAN04 in cancer treatment, the company gets a risk spreading that according to the board of directors is considered very attractive. In addition, the knowledge and tools developed within the CAN04 project gives a pronounced synergy between the two projects. "The goal is that within our existing or new antibody libraries identify and optimize antibodies that inhibit both IL-1 and IL-33 activity to treat autoimmune and inflammatory diseases", says Göran Forsberg. Planned future capitalization process In order to carry out the activities presented above, Cantargia’s board assess that the company has an additional need of capital of about MSEK 80 until mid 2018, in addition to what has been previously announced. Further information on the planned capitalization is planned to be published in Q4 2016 or Q1 2017. In addition, the capitalization also includes the conversion of warrants of series TO 2 and TO 4 in October 2016. If fully exercised, these warrants add a total of about MSEK 25 before issue costs to Cantargia. Cantargia’s board is expected to evaluate the opportunities and strategic options available for the company's next development stage during mid 2018. For more information, please contact:Göran Forsberg, CEOPhone: +46 46 275 62 60E-mail: goran.forsberg@cantargia.comCertified Adviser: Sedermera Fondkommission This constitutes information that Cantargia is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on 20 September 2016, at 8:00 am.

Stem cell researcher from Lund University receives the Fernström Prize

Every year, the Fernström Foundation presents one large Nordic prize (which will be announced later in September) as well as local prizes to researchers at the six faculties of medicine in Sweden. Malin Parmar has received Lund University’s local prize for her studies on how to repair a brain that has suffered damage due to, for instance, Parkinson’s disease, with the help of advanced methods. Her work involves three different aspects of research:- making stem cells develop into dopamine-producing nerve cells, which can be inserted into the brains of patients who suffer from Parkinson’s, and thus have low levels of the signal substance dopamine - reprogramming skin cells directly into dopamine cells, without having to go through a stem cell stage- inserting genes into the brain to perform such reprogramming on the spot, and making, for example, glial cells (a type of connective tissue) convert into dopamine cells. “I believe in all three methods. They each have their advantages and disadvantages, and very different time perspectives”, she says. The first method will also be the first to be tested, in which stem cells, that have been cultivated in a lab, will be made to transform into dopamine cells to be transplanted into the patient’s brain. Trials with human patients are expected to begin within two years. A characteristic feature of stem cells is that they love to divide and create new cells. This is both an advantage and a disadvantage in this context. The advantage is that it is easy to obtain large quantities of cells to transplant. The disadvantage is that the division must be monitored carefully, so as to not have the process take off in an uncontrolled manner, similar to what happens in cancer. “Therefore, before the method can be applied on a larger scale, we need to conduct major and time-consuming safety trials, which can be expensive”, says Malin Parmar. The second method does not have the same disadvantage. Here it is possible to take skin cells from patients themselves – cells that could be directly converted into dopamine cells. There would then be no cell division and therefore less risk of uncontrolled development. Furthermore, by using the patient’s own cells, the risk of rejection is minimal. A few years ago, Malin Parmar’s group became the first in the world to successfully reprogram skin cells into nerve cells. Because the technology is so new, a clinical application of the method is further ahead: it might take 8–10 years before the method is ready to be tested on patients. The third method does not involve a transplantation of cells; rather, it is about inserting healthy genes into a diseased brain. In other words, the transformation does not take place inside a test tube, but in the actual brain. Malin Parmar’s group was first to successfully perform this as well. “Through animal testing, we were able to show that it is possible to reprogram glial cells (a type of cell that is found in large quantities in the brain) into nerve cells”, she says. However, the former glial cells are not to become just any cells, but specifically dopamine-producing nerve cells. It is impossible to say if and when it this development can be controlled. “It could be six months, but possibly also 20 years! However, if we succeed, the other part of the work does not have to be all that difficult”, says Malin Parmar. Gene therapy – i.e. inserting healthy genes into diseased cells in the body with the help of a harmless virus – is a method that is already used to treat different genetic diseases. The prize awarded by the Fernström Foundation will be presented to the Lund researcher during the popular science event “Research Day” in Lund on 2 November. Contact Professor Malin ParmarTel: +46 (0)46-222 06 20, Mobil: +46 (0)70-982 39 01E-mail: malin.parmar@med.lu.se FACTS ABOUT FERNSTRÖM: · Every year, the Eric K Fernström Foundation awards a prize of SEK 100 000 to “young, particularly promising and successful researchers” at the six faculties of medicine in Sweden. · The foundation also awards a large prize of SEK 1 million to a medical researcher from one of the Nordic countries. The name of this year’s prize recipient will be announced on 26 September. · Eric K. Fernström’s six local awards and the major “Nordic prize” are presented at the popular science event “Research Day” which takes place on 2 November in Lund. On this day, journalists who so wish will have the opportunity to meet with the prize recipients.

DOF SUBSEA REDERI AS - SALE OF SKANDI SANTOS.

AKASTOR ASA (AKA) has today published a press release containing information on the establishment of a joint venture under establishment between AKA and other interests which, inter alia, will acquire the vessel SKANDI SANTOS (the “Vessel”) by agreement with DOF Subsea Rederi AS. The sale releases approx. NOK 350 mill in liquidity after coverage of all costs and repayment of debt. DOF Subsea Rederi AS has been the Vessel’s registered owner since its delivery in 2009. The Vessel has since then served under a bareboat charter contract with AKOFS, a company in the AKASTOR Group. Norskan Offshore Ltda. of Rio de Janeiro, Brasil (Norskan), a subsidiary of DOF ASA, has since the Vessel was delivered been the marine manager and marine personnel operator under separate contract with Petrobras, under which the Vessel has been and will continue to be engaged. The services of Norskan will continue unchanged. DOF Subsea ROV AS, a subsidiary in the DOF Subsea AS Group, will continue to own and provide ROVs, and its affiliate DOF Subsea Servicos Ltda. in Brazil will continue to provide ROV services onboard the Vessel, all as part of the Subsea Equipment Support Vessel Contract with Petrobras. For the services to be provided pursuant to the other contracts under which DOF companies will serve will contribute to positive results annually throughout the remaining contract period. Mons S. Aase, CEO of DOF ASA and DOF Subsea AS, says: “The Vessel has been a great success for all involved since its delivery. The companies in the DOF ASA and DOF Subsea AS Group are much looking forward to continuing the excellent cooperation with AKASTOR and its affiliates in this successful venture, the values of which we fully share.” The agreement to sell the Vessel to the AKASTOR JV is subject to Petrobras consent and certain other approvals and conditions, the clearance of which is expected to be forthcoming in Q4 2016. Contact person: CEO Mons S. Aase, +47 91 66 10 12 CFO Hilde Drønen, +47 91 66 10 09

Industrifonden strengthens its Life Science team

Before joining Industrifonden, Patrik Sobocki held the position of European Chief Operating Officer for the business area Real World Evidence at IMS Health, the world’s leading provider of information and technology services to the healthcare industry. The role included responsibility for IMS Health’s M&A strategy within Real World Evidence. At Industrifonden, Patrik will focus on developing the current investment portfolio, as well as on new investments, primarily within digital health. – Industrifonden continuously strives to secure high-quality and up-to-date understanding of our core investment areas. Patrik’s thorough knowledge of health economics and its impact on the health care sector’s willingness to pay, combined with his experience in digital health, will be a significant contribution to our team, says Nina Rawal, Head of Life Science at Industrifonden. Prior to his employment at IMS Health, Patrik has led two startup companies, most recently in a role as CEO at Pygargus, which was acquired by IMS Health in 2013. Patrik holds a M.Sc. in Economics and Finance from Stockholm School of Economics, as well as a Ph.D. in health economics from Karolinska Institutet. He is currently an Associate Professor at Karolinska Institutet, where he supervises both undergraduate and graduate students in health economics. – Based on my experience as an entrepreneur, as well as from acquiring startup companies, I look forward to contributing to strengthen Industrifonden’s position within the area of life science in general and digital health in particular. I am proud to become a part of a professional and tight team with a sharp eye for identifying and developing the successful companies of tomorrow, says Patrik Sobocki. Industrifonden is one of the Nordic region’s most active investors in the Life Science area, with a focus on pharmaceuticals, medtech and digital health. Industrifonden's current holdings include Pharmalink (http://industrifonden.com/portfolio/pharmalink/), BONESUPPORT (http://industrifonden.com/portfolio/bonesupport/) and AMRA (http://industrifonden.com/portfolio/amra/).

HiQ NOMINATED IN SWEDISH PUBLISHING AWARDS WITH THE MUNICIPALITY OF KUNGÄLV

“We’re very happy! One of the goals was to be ground-breaking in terms of design for municipality web sites, and create something completely new and more user-friendly, simplifying for everyone who live and work in Kungälv. A site that inspires, builds pride, and that is not a colossus of information. This nomination shows us that we, together with Kungälv, have succeeded,” says Jessica Söderbäck, client manager at HiQ.  HiQ has had an overall responsibility for both design and development. The old site has decreased from 15,000 to 800 pages and been replaced by a solution with improved logic, better search functionality, translations to sign language, and an emphasis on visual communication. Accessibility has been in focus throughout the project.   ”The communications unit in Kungälv produces all videos and images on its own. We want the site content to be local and professional. It needs to be evident that video is one of our main tools for reaching the citizens, and I think we have succeeded in that. Our keywords are re-thinking, courage, and creativity,” says Susanne Junkala, Head of communications at Kungälv municipality. “Digitalisation affects us all and makes it possible to simplify people’s everyday lives, not least in the public sector. At HiQ we have the know-how and experience to carry the responsibility on a strategic, creative, and technical level. We’re very proud of this nomination and of the trust from our brave client,” says Lars Stugemo, president and CEO at HiQ. HiQ also wins its fourth nomination in a row for HiQ Magazine (https://issuu.com/hiq-media/docs/hiq_magazine2016_eng) (Client Magazines B2B). In 2015, the publication won a Publishing Award in combination with HiQ’s Annual Report. “We’re very excited to see HiQ Magazine acknowledged for the fourth straight year, both in this competition and earlier in the Swedish Design Awards. HiQ Magazine is not a conventional customer magazine and it makes us proud that our ambition to push the limits is appreciated. The team, both here at HiQ and at Kärnhuset, have done an amazing job,” says Jenny Normark Sperens, Head of Communications at HiQ. The winners of the Swedish Publishing Awards (http://www.sppriset.se) are announced on November 14th. For more information, please contact: Jenny Normark Sperens, Head of Communications, HiQ. Tel. +46 734 431 007

Farstad Shipping ASA – Concentrates its activities in Australia

Farstad Shipping concentrates its oil service activity in Australia to Perth and will close down the management office in Melbourne. Consequently, the Australian onshore organization will be reduced from 65 to around 30 employees. - Farstad Shipping has participated in the development of the offshore oil and gas industry in Australia since the 1990s, and has become one of the leading oil service companies in the region. To secure this position also in the future, we are now transferring all of our activities to Perth, making it our new headquarters in Australia, says Karl-Johan Bakken, CEO of Farstad Shipping. Perth will then facilitate both the headquarters and the operations centre, in addition to the company’s training and offshore simulation centre.   The background for this move now, is the challenging market situation with low oil price and the subsequent sharp reduction in offshore activity. In connection to these changes, the Australian onshore organization will be reduced from 65 to around 30 employees. - It is with regret that we have to lay off dedicated and highly skilled employees, but it is the unfortunate result of a necessary capacity adjustment, Bakken says. The CEO would like to thank all of his employees who have contributed in building up Farstad Shipping in Australia. Bakken further says that the transfer of activity from Melbourne to Perth is a necessary step in preparing Farstad Shipping for the future. - In addition to working on establishing an overall refinancing plan, we are continuously working on structural solutions in order to secure our competitiveness and to align with the market and the needs of our clients, Bakken concludes. Farstad Shipping Pte. Ltd. in Singapore, which previously has been reporting to Australia, is now to be directly related to the Head Office in Aalesund. Contacts for further information: CEO Karl-Johan Bakken – tel. +47 901 05 697 CHRO Knut Åsebø – tel. +47 916 14 771 Farstad Shipping’s fleet currently consists of 57 vessels (29 AHTS, 22 PSV and 6 SUBSEA) and 1 SUBSEA vessel under construction. The company’s operations are managed from Aalesund, Melbourne, Perth, Singapore, Macaé and Rio de Janeiro with a total of 1,780 employees engaged onshore and offshore. The company’s strategy is to be a leading quality provider of large, modern offshore service vessels to the oil industry. www.farstad.com 

Tieto appoints Alexandra Drevenlid as Chief Digital Officer

Alexandra Drevenlid joins Tieto from Tele2, where she has held several leadership roles during the past decade, most currently as Director Network & IT and Chief Technology and Information Officer. Prior to her long career at Tele2, Drevenlid was Director of Marketing at Dynarc Ab and Head of Engineering at GlobalOne Services AB. “Tieto is currently entering a very exciting phase of accelerating innovation and growth through a new strategy and investments into services and solutions such as Customer Experience Management, cloud services and Internet of Things. I am thrilled to join Tieto and turn the digitalization opportunities in the market into an enhanced experience for Tieto’s customers and employees,” says Alexandra Drevenlid. “Alexandra brings with her over 20 years of experience at the intersection of technology and customer experience. I am truly delighted that she joins Tieto to enhance our customers’ experience of Tieto’s digitalized services and related innovation ambitions. Alexandra will play a crucial role driving the digital development of our company, thus further increasing the value for our ecosystem of customers, employees and partners,” says Kimmo Alkio, President and CEO. “ Drevenlid starts in her position on 1 October 2016 and will be based in Stockholm. She reports to President and CEO Kimmo Alkio. For further information, please contact:Kia Haring, Head of Global Communications: kia.haring[at]tieto.com, +358 40 765 3700 TIETO CORPORATION DISTRIBUTIONPrincipal media Tieto aims to capture the significant opportunities of the data-driven world and turn them into lifelong value for people, business and society. We aim to be customers’ first choice for business renewal by combining our software and services capabilities with a strong drive for co-innovation and ecosystems. Headquartered in Finland, Tieto has over 13,000 experts in close to 20 countries. Tieto’s turnover is approximately EUR 1.5 billion and shares listed on NASDAQ in Helsinki and Stockholm. www.tieto.com

Itiviti wins Technology Innovator Award by CV Magazine

Corporate Vision is dedicated to working around the clock to shine a spotlight on the brightest, best performing and most deserving companies and individuals from around the business world. The 2016 Technology Innovator Awards were designed to recognize and reward the individuals, departments and firms behind the ground-breaking developments that change the way we do business for the better. “We are pleased to affirm that Tbricks by Itiviti measures up to the high standards set for the CV Technology Innovator Awards,” said Laura Hunter, Awards Co-ordinator, Corporate Vision Magazine. “We are passionate about recognizing outstanding achievement, game-changing innovation and stellar performance, which Itiviti has convincingly demonstrated with their next generation trading platform.” The Corporate Vision Awards are decided by a combination of votes gathered from the magazine’s network of industry partners and in-house research performed by industry insiders and corporate specialists. Each award is carefully scrutinized, from a nominee's region to their performance over the past 12 months, their commitment to innovation, their methods and even their competition. “We are really proud over the recognition as a leading technology innovator as we would like to think that we are pushing the boundaries in trading technology,” said Jonas Hansbo, Chief Strategy Officer, Itiviti. “The CV Technology Innovator Award adds an important, independent certification to the platform, and we see this as further acknowledgement of what our customers and users are telling us.” Tbricks by Itiviti is the first trading platform designed from the ground up for today’s trading reality: built to be customized, scaled, co-located and blazingly fast. Its app-based architecture combines the tailored functionality of an in-house built system with the convenience of a third party solution. By providing the source code to its library of apps, Itiviti allows clients to add their own unique sets of functionality and unlock new capabilities in response to changing market requirements or their own proprietary needs.  About ItivitiItiviti is a world-leading technology provider for the capital markets industry. Trading firms, banks, brokers and institutional clients rely on Itiviti technology, solutions and expertise for streamlining their daily operations, while gaining sustainable competitive edge in global markets. With 13 offices and serving more than 400 customers worldwide, Itiviti was formed by uniting Orc Group, a leader in trading and electronic execution, and CameronTec Group, the global standard in financial messaging infrastructure and connectivity. From its foundation in 2016, Itiviti has a staff of 400 and an estimated annual revenue of SEK 700 million. Itiviti is committed to continuous innovation to deliver trading infrastructure built for today’s dynamic markets, offering highly adaptable platforms and solutions, enabling clients to stay ahead of competitive and regulatory challenges. Itiviti is owned by Nordic Capital Fund VII. www.itiviti.com For further information, please contact:Jonas Hansbo, Chief Strategy Officer, Itiviti, Tel. +46 70 652 51 93Christine Blinke, Chief Marketing Officer, Itiviti, Tel. +46 739 01 02 01

Oncology Venture enters development deal with Cadila Pharmaceuticals on LiPlaCis® and its Drug Response Predictor

“Cadila is one of the largest privately held pharma companies in India. The transformational partnership with Cadila places Oncology Venture in another league. Together with Cadila we aim to take LiPlaCis® and its Drug Response Predictor – DRP -  through a strong and focused development program with the goal of receiving marketing approval. We will together with Cadila who invests heavily as an ‘in kind’ investment test LiPlaCis® in four promising indications: breast, head & neck, skin and esophageal cancer which gives the drug a really good chance to benefit patients who are likely to respond,” says Peter Buhl Jensen, M.D., CEO of Oncology Venture. “In this partnership OV has the opportunity to build a much larger value instead of selling it outright. Cisplatin is one of the most used drugs in cancer treatment and the potential sales with the improved LiPlaCis formulation is huge,” Buhl Jensen further comments. On this occasion, Dr. Rajiv Modi, Chairman and Managing Director, Cadila Pharmaceuticals Ltd., said, “Cadila Pharmaceuticals believes in providing world-class healthcare products to improve quality of life of patients. This agreement with Oncology Venture is an affirmation of our commitment to develop novel treatment for those diseases in the realm of unmet medical needs. Cancer affects millions of people around the globe. We look forward to developing the product to benefit millions of patients who are affected by the deadly disease.”The Partnership dealThe deal with Cadila Pharmaceuticals will finance and perform studies in a total of 310 cancer patients with highest likelihood of sensitivity to LiPlaCis. The deal covers the following:1. Screening by the use of the LiPlaCis-DRP™ of 1 250 metastatic breast cancer patients to identify 250 patients with high likelihood to respond to LiPlaCis treatment and perform a randomized phase 3 trial in these 250 patients comparing standard therapy with LiPlaCis.2. Through Cadilas strong network and Cadilas CRO run four (4) clinical Phase 2 trials in 20 patients (out of 100 screened) with Head & Neck cancer, 20 prostate cancer patients (out of 100 screened), and 10 skin cancer patients and 10 esophagus cancer patients – the two latter indications are in a high frequency sensitive to cisplatin – of which LiPlaCis® is an improved formulation – why the patients will not be screened. Cadila has commercialization rights in India, Russia, Africa and South East Asia (ASEAN countries only), Oncology Venture has the commercialization rights to America, Europe and China and RoW. Oncology Venture will be responsible for the manufacturing and pay for manufacturing of the product. Estimated costs for product in 2017-2018 is 0,6 MUSD. In the consortium of owners now including Cadila Pharmaceuticals, LiPlasome, MPI and Oncology Venture - Oncology Venture owns 29% of the total value of the LiPlaCis project after Phase 3. When developed parties may choose to market themselves in their own territories or out license or sell to a third party. About the LiPlaCis license from LiPlasome Pharma and the DRP license from MPIOncology Venture has in-licensed LiPlaCis® from LiPlasome Pharma and the LiPlaCis DRP™ from MPI and has now entered a development partnership with Cadila Pharma. The financial impact is as follows: In the consortium of owners now including Cadila Pharmaceuticals, LiPlasome, MPI and Oncology Venture - Oncology Venture owns 29% of the total value of the LiPlaCis project after Phase 3.OV pays for the manufacturing of the product. Oncology Venture did not pay any upfront payment to LiPlasome but pays 2x9 MUSD in sales milestones to LiPlasome once LiPlaCis is commercialized either via a partner or sold on the market. (please see latest company prospectus).Cost of clinical trials in oncology all phases per patient 59.500 USD (PhRMA 2013).http://www.phrma.org/sites/default/files/pdf/biopharmaceutical-industry-sponsored-clinical-trials-impact-on-state-economies.pdf  About Cadila Pharmaceuticals (www.cadilapharma.com)Cadila Pharmaceuticals is one of the largest privately held pharmaceuticals companies in India, headquartered at Ahmedabad, Gujarat, India. Established in 1951, the company develops and manufactures pharmaceutical products and sells and distributes these in all major markets across the globe.  It is an integrated healthcare solutions provider with a comprehensive therapeutic basket including oncology, pulmonology, neurology and cardiovascular.Cadila Pharmaceuticals is a research and innovation driven company and has collaborations with premier academic and research-based organisations across the world.Cadila Pharmaceuticals was the first Indian company to get IND approval by USFDA for clinical trials to be conducted in India. Subsequently, the company has filed 5 INDs with the USFDA. About LiPlaCisCisplatin is one of the most widely used drugs in the treatment of cancer due to its documented efficacy in a number of tumour types. Cisplatin is used in the treatment of large indications as lung cancer Europe+US ≈ 673,000 new cases annually), head and neck cancer (500,000 cases annually worldwide) bladder cancer (EU+US ≈ 170,000 annually) and ovarian cancer (EU+US ≈ 71,000 annually). The lipid formulation from LiPlasome is the answer to a well-established need for improving cisplatin therapy and improving the formulation of the drug, so that a more selective up-take of cisplatin administered takes place at the tumour sites. LiPlasome Pharma ApS has identified and incorporated a mechanism into their liposomes - called LiPlasomes - designed to trigger the release of an encapsulated drug specifically in the tumour tissue. An enzyme especially present on tumors called secretory phospholipase A2 (sPLA2), is utilised to break down the LiPlaCis once it has accumulated in the cancer tissue. The lipid composition of the LiPlasomes is tailored to be specifically sensitive to degradation by the sPLA2 enzyme and thereby for release of the encapsulated drug. The technology behind LiPlaCis® was originally developed by scientists from Danish Technical University -DTU. More about LiPlaCis™ and the clinical testingThe Phase 1 study to evaluate the safety and tolerability of LiPlaCis in patients with advanced tumours is running at a two University Hospitals in Copenhagen and has included 21 patients and is now in its extension phase where patients with metastatic breast cancer screened for sensitivity to LiPlaCis by the DRP are included. LiPlaCis has demonstrated promising signs of good activity in a small number of patients in the ongoing study. LiPlaCis™ is administered intravenously in 3 weeks cycles on day 1 and day 8. Upon the investigator’s judgement the patient may continue treatment for more than 3 cycles when benefiting from the study drug. About the Drug Response Predictor - DRP™ screening toolOncology Venture uses the MPI multi gene DRP™ to select those patients that by the gene signature in their cancer is found to have a high likelihood of response to the drug. The goal is to develop the drug for the right patients and by screening patients before treatment the response rate can be significantly increased.This DRP™ method builds on the comparison of sensitive vs. resistant human cancer cell lines including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP™ is based on messenger RNA from the patients biopsies.The DRP™ platform i.e. the DRP™ and the PRP™ tools can be used in all cancer types, and is patented for more than 60 anti-cancer drugs in the US. The PRP™ is used by MPI for Personalized Medicine. The DRP™ is used in Oncology Venture for drug development. About LiPlaCis sales potential in breast cancer and lung cancerProvided that LiPlaCis has activity in the same diseases as cisplatin the below serves as examples of two major indications where conventional cisplatin is frequently used. LiPlaCis sales potential in breast cancer in USA and EU is more than 700 MUSD annually (please see below). For comparison eribulin sales for late stage breast cancer was 390 MUSD in 2013.http://www.eisai.com/pdf/eannual/epdf2014an.pdf  Breast Cancer (BC) in the USAhttp://www.breastcancer.org/symptoms/understand_bc/statistics• 246.600 new cases expected in 2016• 40.450 deaths• 2.8 million with a history of BCThe 40.450 women who died of BC would be candidates to better treatment. If ½ of these are amenable for treatment and 20% would receive LiPlaCis there would be. 4045 women treated – 6 months average treatment of 10.000 USD per month = 242 MUSD. Breast Cancer in Europehttp://eu-cancer.iarc.fr/eucan/CancerOne.aspx?Cancer=46&Gender=2Europe 2012: 458.337 new cases and 131.258 deaths.EU• 358.967 new cases• 90.665 deaths• 9067 women treated – 6 months average treatment 10.000 USD per months = 544 MUSDhttp://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/breast-cancer-statistics  Globally 1.7 million new cases annually. LiPlaCis in lung cancerLung cancer USAhttp://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics• 224.390 new cases in 2016• 158.080 deathsCisplatin is the most important agent in this disease. If LiPlaCis is preferred and given by DRP in• 20% of cases• 44.880 patients treated 4 months average 10.000 USD per month = 1.795 billion USD Lung cancer Europehttp://www.lungcancereurope.eu/wp-content/uploads/2015/11/LuCE-EU-Policy-Position-Paper-2015-IMPAGINATO.pdf449.000 new cases in 2015.89.800 patients treated 4 months average 10.000 USD per month = 3.59 billion USDAND: * Head and Neck * Esophagus * Ovarian * Bladder are all potential indications for LiPlaCis. For further information, please contact Ulla Hald Buhl, COO andChief IR & CommunicationsMobile: +45 2170 1049uhb@oncologyventure.com  or Peter Buhl Jensen, CEOMobile: +45 21 60 89 22E-mail: pbj@oncologyventure.com This information is information that Oncology Venture Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on September 20th 2016. About Oncology Venture Sweden ABOncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction – DRP™ – in order to significantly increase the probability of success in clinical trials. DRP™ has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors genes are screened first and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient.The current product portfolio: LiPlaCis for Breast Cancer, Irofulven developed from a fungus for prostate cancer and APO010 – an immuno-oncology product for Multiple Myeloma.

NCC to build new parking garage in Örebro

“The need for more parking spaces has increased in pace with the expansion of specialist care at the university hospital. It is positive that we can now, in partnership with NCC, commence the planning and project engineering phase of the new parking garage that will improve accessibility at the hospital,” says Marie-Louise Forsberg-Fransson, Chairman of the Regional Board. The parking garage will have about 825 spaces that can be utilized by staff and visitors to the hospital. These spaces will be distributed over five open floors above ground, with the top floor comprising rooftop parking and a planned solar cell facility. The ground floor and the underlying basement will be equipped with new premises for goods receiving and a new civil defense shelter. “We are pleased to continue partnering with Region Örebro on more orders in conjunction with the hospital. Our objective is to create an open and secure parking garage with an attractive architectural design,” says Henrik Landelius, Manager NCC Building Sweden. The project is being carried out in the form of a partnering arrangement and the first phase is now being started. This will comprise carrying out detailed costings, construction documents and project engineering. The construction start is planned for mid-2017 and the parking garage is expected to be completed at the end of 2018. The order value of the project is expected to amount to about SEK 250 million and the order is expected to be registered in the third quarter of 2017. NCC has already won an order to a value of SEK 1.5 billion for the construction of the new H building at the University Hospital of Örebro. The construction period for this project will be from 2016 through to 2020.

New London Architecture and Planning Company Achieves Exceptional Growth

A New London based Architecture and Planning Consultancy has achieved both exceptional growth and satisfied customer feedback since launching two months ago. Design Architecture is now focussing on future growth and aiding more clients through their combined architectural and planning services.   In the first month of operation, Design Architecture’s turnover was just £2,000 but this increased to over £15,000 the following month thanks to the 32 planning projects the company has completed. Looking ahead the firm expects more growth, achieving £40,000 turnover in month three and doubling its current five-person team by the end of the year. Design Architecture’s accomplishment can be linked to both its 100% success rate and its excellent customer service. The company offers a full design and build process for clients, with both transparent pricing and full refunds offered if planning permission through the company is not achieved for both of their residential and commercial clients. Tony Ridley, Planning Consultant of Design Architecture, said, “The rapid success that Design Architecture has seen so far is a testament to both the talent and professionalism of the whole team. Our unique combined offering of both architecture and planning means that we can assist on more projects and take clients from the design phase right through to construction, making the whole process smoother and more efficient. We’re going to continue to build on the success we’ve already established in the coming months to complete even more small projects as the business grows.” The company has an extensive range of services for both residential and commercial development, including home extensions, loft conversions, garden roof terraces, summer houses, new builds and change of class uses. Design Architecture can also provide Building Regulations, Construction Project Management, Construction Drawings and Interior Design services. Design Architecture is the only Architecture and Planning Consultancy in London to offer a full refund to all clients that do not achieve planning permission. Unsuccessful clients also get to keep all architectural drawings and planning reports for free. Clients that appoint the company for preparing their planning applications also receive free 3D rendered drawings. To find out more visit https://www.desarch.co.uk/. 

Play’n GO breaks the mould with launch of a new category of online casino game

September 20, 2016 – Leading table game and slots specialist Play’n GO has introduced an all-new category of online casino game with the launch of two video bingo titles. The premium games, Flying Pigs and Bugs Party, were developed in partnership with Latin American land-based video bingo experts Zest Gaming, and are the first online titles available outside the region to combine a slot mechanic with a video bingo display. Flying Pigs transports players to a rural countryside setting where the farm comes alive. Up to four bingo cards hold 15 randomly generated numbers during each game. Half of the 60 balls are drawn randomly, with players that are one number away from winning able to make hay by triggering an extra ball. Bonus games are available to players who match a pattern shown inside the fenced-in area on screen, with players able to move the friendly pigs inside their pen to reveal further prizes. Revealing the evil boar will signal the end of the bonus game. Bugs Party has a similar mechanic to its twin game Flying Pigs, but with a hungry frog and an angry pest control officer out to stop players from guiding their troupe of crazy bugs to winning combinations. Jars of delicious jam attract bugs to big wins in the lucrative bonus round, with players able to multiply their winnings by a factor of eight by triggering an extra ball. Both Flying Pigs and Bugs Party were developed in partnership with Latin American land-based video bingo experts Zest Gaming and come complete with high-definition animation and smooth performance across phone, tablet and desktop versions. Johan Tornqvist, CEO of Play’n GO, said: “Flying Pigs and Bugs Party are games the likes of which many in the industry won’t have seen before. It’s thrilling to be able to introduce an all new category of online casino game. Video bingo has proved exceptionally popular as a land-based game in Latin America and we’re confident that our innovation will be a big hit in the rest of the world. “Players with a slot or bingo background will flock to the two premium titles Flying Pigs and Bugs Party and we’re sure operators will delight in the response to our all-new product line.” Play’n GO’s games are now prominent on the sites of 100 operators in more than 40 languages.

ExpreS2ion and VaxInnate Sign Research License Agreement

The Research License Agreement VaxInnate has decided to continue its proprietary vaccine research with ExpreS2, which was initiated under a simple Material Transfer and Use Agreement (“MTA”) in 2015, under a new Research License Agreement (“RLA”). The RLA grants VaxInnate the right to conduct research based on ExpreS2 for one year, until August 2017. The agreement has no immediate significant financial impact on ExpreS2ion, but it has the potential for future revenues from new commercial licenses, if VaxInnate bring products based on the ExpreS2-platform into clinical development. Furthermore, this expands the use and demonstrates the functionality of the ExpreS2-platform. About VaxInnate VaxInnate Corporation is a privately-held biotechnology company in Cranbury, NJ, USA, that is pioneering breakthrough technology for use in developing novel vaccines. Its vaccine platform is based on Toll-like receptor (TLR) technology, which dramatically improves vaccine immunogenicity and efficacy. The technology involves genetically fusing vaccine antigens to the bacterial protein flagellin, a potent stimulator of the innate immune system. VaxInnate’s current focus is on vaccines for infectious diseases, including seasonal and pandemic flu, RSV, dengue and Zika.  Steen Klysner, CEO, ExpreS2ion, comments“We are pleased that an accomplished partner as VaxInnate wishes to continue their vaccine research with our proprietary ExpreS2 platform. The combination of Vaccinates proprietary vaccine technology and our platform enable efficient development of new and exciting products and we look forward to the results "Certified Advisor Sedermera Fondkommission is appointed as Certified Adviser for ExpreS2ion.

Boost Your Home Appeal with A Bespoke Kitchen from Dimora

Boosting the appeal – and the value – of your entire home has never been easier, with the bespoke kitchen design services available from new interiors firm, Dimora. Dimora firmly believes that the kitchen is the heart of the home. It’s where family meals are made and enjoyed, it’s where guests gather to laugh and chat – it’s the thriving hub of any family property. With bespoke design services and a focus on classic Italian design, Dimora is helping homeowners to revamp their kitchens and ensure they’re tailored to every client’s specific needs. Andressa Perondi, Managing Director, of Dimora, says, “We firmly believe that every home needs a beautiful kitchen. It boosts the appeal of the entire property, and offers a welcoming place for family members and guests to relax, enjoy their surroundings and tuck into a home-cooked meal. Here at Dimora, we offer a range of beautiful kitchen products, as well as a bespoke kitchen design service that caters to your exact needs.” Installing a beautiful new kitchen can also have a positive impact on the value of a home – great news for homeowners in the current competitive housing market. Experts have calculated that the average kitchen renovation costs around £6,000, but could increase the value of your entire property by as much as 6%. For a home worth £300,000, that’s a staggering increase of £18,000. Andressa adds, “As well as boosting the appeal of your home, installing a bespoke kitchen is the perfect way to add value. The kitchen is one of the most-used rooms in the house, and having a brand new, professionally designed and installed kitchen is one way to ensure you’ll be flooded with offers from potential buyers, should you eventually decide to sell.” With a range of beautiful, functional products all under one roof, Dimora is set to be the go-to destination for anyone hoping to bring some true Italian style into their home. For those who are considering renovating their kitchen, Dimora is holding a live cooking event at its brand new showroom in the heart of Chelsea. The event takes place on 27thSeptember, and will give visitors the opportunity to see some of the Dimora products in action, as well as chatting with the qualified architects and interior designers about their range of services. For further details, visit the website: www.dimora.co.uk

Preselected Couture invites investments to capitalise on lucrative secondary luxury goods market

New web based community and marketplace, Preselected Couture provides an attractive investment opportunity as it launches its crowdfunding campaign. The scalable platform for buying and selling pre-owned designer fashion, accessories and homewares invites funding to develop its business, as experts predict the secondary luxury goods market is set to grow to £400 bln.  Already a hit amongst its client base, the online marketplace startup has achieved over 40,000 website visits and 300 registered users since its launch in May, becoming a trusted choice amongst its community of users. Funds from investors will be used to improve the website and to accelerate its marketing efforts, capitalising on the emerging lucrative market of second hand, designer goods. Preselected Couture is founded by Maria Mueller and Maria Rachinskaya, with a combined 40 years’ experience in mathematics, corporate finance, and project management. Its board of directors have extensive experience in company management, luxury goods and lifestyle brands. Maria Mueller, Co-Founder and Director of Preselected Ltd said, “Preselected Couture responds to growing consumer trends, catering to the developing ‘sharing economy’ and desire for a different purchasing experience. Our success after just five months has proven our relevance and our exciting future that lies ahead. Now, as the secondary luxury market is set to grow, we want to refine our business to capitalise on this sensational opportunity.” Preselected Couture offers affiliate programs for professional vendors and existing retailers who sell through the platform, presenting an attractive and unique business opportunity compared to competitor websites such as Ebay. The company projects its revenue to be over £430k by the end of 2017, making it a great addition to any portfolio of investment.  All designer items sold via the peer to peer marketplace undergo thorough screenings for authenticity, brand relevance and condition, enlisting confidence in its customers that are searching for high-end, luxury goods. Preselected Couture offers sellers an innovative platform to free up space, unleash cash from their possessions, and even to turn these profits into charitable donations. Preselected Ltd is offering 10.71% equity for £120,000 investment target, raised under the SEIS tax relief scheme. All investors are subject to an attractive rewards programme, offering gift cards from luxury brands such as Hermes and Prada that provide an appropriate present to welcome supporters of the growing designer marketplace.    Maria Mueller continued, “With Preselected Couture, we have created a forward thinking website using a formula that is proven to work. However, we offer a unique experience to make it stand out from its competitors. As the demand for secondary luxury goods is set to grow, so are we, with a scalable platform that can extend both internationally and through the products that we can sell.” The campaign closes on 8thOctober 2016. To find out more about Preselected Couture and to take advantage of the investment opportunity, visit https://www.crowdcube.com/preselected Browse the carefully selected luxury products and learn how the platform works at https://preselectedcouture.com/

Alimak Group divests the US Rental operation to Bigge Crane and Rigging

Alimak Group operates a small rental business in the US, whose origins predate the merger between Alimak and Hek in 1999. The US Rental business has been operated as a separate unit within the Alimak US operation. The divestment will allow a stronger focus on product sales as well as after sales services supporting Alimak´s entire product portfolio in the US and Canada.  “The divestment is a logical step in Alimak Group´s strategy of growth in its core business as it allows our US operation to fully focus on further expansion of our broad offering of products and aftersales services in North America. Bigge is one of America´s premier global crane companies and has been a long and valuable customer to Alimak. They have a vast experience of working with Alimak equipment and I feel confident that our existing rental customers will see benefits from the new owner” says Tormod Gunleiksrud, CEO of Alimak Group. “Bigge is pleased to add Alimak’s US Rental business to our operation. Bigge has an extensive network of locations and expertise in rental of construction hoist and related equipment, and this addition is consistent and synergistic with our core business. Bigge has had a long term relationship with Alimak, and Alimak product is central to Bigge’s existing fleet of construction hoist and related equipment,” says Weston Settlemier, CEO of Bigge Crane and Rigging Co. The US Rental business had in 2015 a revenue corresponding to approximately 1% of the Group´s total revenue. For business area Rental the corresponding figure was 9%. The purchase price amounts to USD 2.4 million. Alimak Group´s Rental business area provides rental services on Alimak´s construction hoists and platforms to customers in four key markets: France, Benelux, Germany and Australia as well as offers sales of Alimak´s used construction equipment. The divestment will be subject to customary regulatory approvals and is expected to close before year end 2016. For further information:Tormod Gunleiksrud, CEO of Alimak Group, Phone: +46 8 402 14 00Sofia Wretman, Head of Communications & IR of Alimak Group, Phone: +46 8 402 14 41 This information in this release is such that Alimak Group AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 18.00 CET on September 20, 2016. About Alimak GroupAlimak is a global market leader and pioneer in designing, developing, manufacturing, distributing and servicing industrial and construction vertical access solutions. The company provide high quality hoists, elevators and platforms primarily for the industrial and construction sectors. Alimak has a global sales, services and distribution platform across more than 70 countries with strong market positions. The company has a well-established and highly resilient aftersales business and its large global installed base of ca. 22,000 units provides unique know-how into its customer’s needs. Alimak was founded in 1948, is headquartered in Stockholm and employ over 1,200 people across the world. The Group had revenues of over 2000 MSEK in 2015. www.alimakgroup.com   About Bigge Bigge is 2016 celebrating its 100th anniversary as one of America’s premier crane sales, crane rental, and project services companies. Bigge provides heavy lifting, heavy rigging, specialized transportation, equipment, and innovative engineering solutions for some of the most challenging projects across the U.S. Bigge currently owns and maintains one of the largest inventory of new and used cranes for sale in the U.S. and globally. www.bigge.com 

Scania creates the world’s first clock made of trucks

When you operate in long haulage transport, being at the right place at the right time can make or break your business. This is why Scania put its new generation of trucks and services through the toughest test of them all – time itself. The process of setting up the world’s first clock consisting entirely of trucks required 14 trucks, 90 drivers and 750,000 square feet of deserted airfield. The gigantic truck clock will start ticking on September 20th at 19.00 CET and be broadcast online. “Trucks are huge, powerful machines, but they’re also intricately designed, refined instruments. Just like watches. Each truck had to be optimized for its specific task in the clock, and real-time monitoring and analysis through our connected services made the whole operation possible”, explains Staffan Arvas, Head of Marketing Communications, Scania. The trucks that made up the clock faced a variety of difficulties depending on which clock hand they were forming. The trucks that made up the second hand had to drive on a round track in a perfect circle every 60 seconds for 24 hours. The inside truck had to maintain a constant speed of 13 km/h, while the outside truck had to hold a constant speed of 53 km/h. For the trucks making up the minute and hour hands, the challenge was to ensure a perfectly synchronized sequence of starts and stops. In order to maintain a correct, even speed while minimizing fuel consumption, each truck had to be carefully managed depending on their position in the clock. Scania fleet managers in the control tower were able to keep track of all the trucks and constantly monitor the status of each vehicle to avoid unexpected stops and keep wear and tear to a minimum. The drivers played a key role in ensuring that the whole operation worked smoothly. Elin Engström, a truck driver at Scania, played a lead role in the second hand that all the other trucks had to follow. She explains: “The most demanding challenge in long haulage is precision and punctuality. The clock was the ultimate test of staying in your line, maintaining your speed and keeping track of every second for 24 hours straight. All the drivers had to be in perfect sync and precision was the key to achieving this”. The clock was filmed using five different cameras, which allows viewers to switch between different angles on the website. Visitors to the site can also learn more about the project and the new generation of Scania trucks and services. The clock was set up to prove that regardless of whether you are hauling grain or fuel, transporting timber or building a 750,000-square-foot clock – Scania can always offer a solution tailored for the only business that matters. Yours. Check out the clock at: scaniaclock.com For more information, contact: Staffan Arvas, Head of Marketing Communications, Scania, tel +46 8 553 832 53, e-mail staffan.arvas@scania.com

NORDIC NANOVECTOR ASA – CHANGES TO THE BOARD OF DIRECTORS AND NOTICE OF EXTRAORDINARY GENERAL MEETING

Renee Tannenbaum has informed Nordic Nanovector ASA ("Company") of her resignation from the board of directors for personal reasons. The board of directors wishes to thank Renee Tannenbaum for her contribution during the period she has served as a board member. The nomination committee proposes that Renee Tannenbaum is replaced by Joanna Horobin and the Company has today called for an extraordinary general meeting to be held on 12 October 2016. The notice of the extraordinary general meeting and the nomination committee's proposal are attached.This information is disclosed in accordance with the Norwegian Securities Trading Act Section 5-12.For further information, please contact:Tone Kvåle, Chief Financial OfficerCell: +47 91 51 95 76Email: ir@nordicnanovector.com About Nordic Nanovector:Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018.Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab (previously referred to as HH1), conjugated to a low intensity radionuclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulatory submission anticipated in 1H 2019.Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat multiple selected cancer indications. Further information about the Company can be found at www.nordicnanovector.com

Polygiene teams up with Fogni, Korean fiber filling manufacturer, for odor-free home textiles and furniture

The alliance combines Polygiene’s expertise in odor control technology with Fogni’s market-leading manufacturing processes to deliver safe, antibacterial and odor-free fiber filling to a broad range of home textiles, bedding and furniture manufacturers to meet South Korea’s growing consumer and commercial demand for healthier mattresses and home furnishings. In September 2016, Polygiene Odor Control Technology with its antibacterial functionality will debut in filler for bedding and sofas that Fogni has provided to well-known Korean brands, including Heail Plus, Halo World, Jakomo, Doldam and Milk Namu. “Our mission is to create safer home environments and healthier lives for our customers,” says Choong Su Kim, CEO, Fogni Co. Ltd. “Increasingly more of our customers are aware of and ask for the benefits of odor-control technology. Polygiene helps do away with unpleasant odors that can arise from using home textiles and furniture while ensuring a safe, antibacterial environment. Our collaboration with Polygiene will help make the homes of our customers healthier places to live.” “Our partnership with Fogni broadens Polygiene a foothold in the home textiles, hospitals, hotels for bedding, and furniture market,” says Christian von Uthmann, CEO, Polygiene. “We look forward to continued cooperation to introduce odor-free filling for an even wider range of home furnishings, large and small – from mattresses and sofas to comforters and cushions.” About FogniFogni Co. Ltd. is the Republic of Korea’s leading manufacturer of functional, environment friendly fiber filling for home textiles and furniture as well as bedding for use at home, hospitals and hotels. ISO 9001- and ISO 14001-certified, the company produces filling for use in a variety of products – from mattresses, comforters and pillows to furniture. www.fogni.co.kr   Find press images here  (http://ir.polygiene.com/en/press/media/images/) This information is information that Polygiene AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 07.45 CET on September 21, 2016.

Nomination Committee appointed for Electrolux Annual General Meeting 2017

In accordance with decision by the Annual General Meeting, Electrolux Nomination Committee shall consist of six members. The members should be one representative of each of the four largest shareholders in terms of voting rights that wish to participate in the committee, together with the Chairman of the Electrolux Board and one additional Board member. The members of the Nomination Committee have now been appointed based on the ownership structure as of August 31, 2016. Johan Forssell, Investor AB, is the Chairman of the committee. The other owner representatives are Marianne Nilsson, Swedbank Robur funds, Kaj Thorén, Alecta, and John Hernander, Nordea Investment Funds. The committee will also include Ronnie Leten and Fredrik Persson, Chairman and Director, respectively, of Electrolux. The Nomination Committee will prepare proposals for the Annual General Meeting in 2017 regarding Chairman of the Annual General Meeting, Board members, Chairman of the Board, remuneration for Board members and, to the extent deemed necessary, proposal regarding amendments of the current instruction for the Nomination Committee. The Annual General Meeting will be held on March 23, 2017, at Stockholm Waterfront Congress Centre, Nils Ericsons Plan 4, Stockholm, Sweden. Shareholders who wish to submit proposals to the Nomination Committee should send an email to nominationcommittee@electrolux.com.

Comment to the first completion of Blackstone’s acquisition of shares in D. Carnegie & Co and request for an extraordinary shareholders’ meeting

Blackstone has also submitted a request to the board of directors in the Company for a notice convening an extraordinary shareholders meeting in order to consider election of board members and chairman of the board of directors in the Company. The board of directors has therefore issued a notice convening an extraordinary shareholders’ meeting, set out in full in a separate press release. Stockholm on 21 September 2016D. Carnegie & Co AB (publ)The board of directors Notice of extraordinary general meeting of D. Carnegie & Co AB (publ) The shareholders of D. Carnegie & Co AB (publ) (the “Company”) are hereby summoned to an extraordinary general meeting on Friday 14 October 2016 at 2 p.m. at Advokatfirman Vinge’s office at Smålandsgatan 20, in Stockholm. The extraordinary meeting is summoned further to the shareholder Vega HoldCo Sarl, a company controlled by Blackstone, representing 28.61 per cent of the total number of outstanding shares in the Company, having requested an extraordinary general meeting in order to resolve on election of board members, election of chairman and remuneration to the board of directors in the Company. Right to attend the general meeting Shareholders who wish to attend the general meeting must be registered in the share register maintained by Euroclear Sweden AB on Friday 7 October 2016, and must also notify the Company of their intention to attend the meeting no later than Monday 10 October 2016. The notification must be made in writing to D. Carnegie & Co AB (publ), Strandvägen 5A, SE-114 51 Stockholm or by e-mail to info@dcarnegie.se. The notification must state the shareholder’s name, personal identity number/registration number, shareholding, address, day time telephone number and information about the attendance of any assistants (maximum two) and, if applicable, information about any proxies. Proxy Shareholders represented by proxy must submit a dated power of attorney. If the power of attorney is executed by a legal person a certified copy of the certificate of registration or equivalent should be attached. The power of attorney and the certificate of registration may not be older than one year, however, the power of attorney may be older provided that the power of attorney according to its wording is valid for a longer period, although, not more than five years. The original power of attorney and the certificate of registration should be sent to the Company at the address mentioned above in good time prior to the general meeting. A proxy form is available at www.dcarnegie.se and will also be sent to shareholders who so and state their postal address.  Nominee-registered shares Shareholders whose shares are registered in the name of a nominee through a bank or a securities institution must temporarily re-register their shares in their own names in order to be entitled to attend the general meeting. Such registration must be duly effected in the share register maintained by Euroclear Sweden AB on Friday 7 October 2016, and the shareholders must therefore advise their nominees well in advance of this date. Number of shares and votes In the Company, on the day of this notice, there are a total of 5,369,866 shares of series A that hold five (5) votes per share at the general meeting and 71,938,910 shares of series B that hold one (1) vote per share at the general meeting. Thus, there are a total of 77,308,776 shares and 98,788,240 votes in the Company. Proposed agenda · 1.                 Opening of the meeting · 2.                 Appointment of chairman of the general meeting · 3.                 Preparation and approval of the voting list · 4.                 Approval of the agenda · 5.                 Election of one or two persons to approve the minutes · 6.                 Determination of whether the general meeting has been duly convened · 7.                 Determination of the number of board members · 8.                 Determination of remuneration to the board of directors · 9.                 Election of board members and chairman · 10.              Closing of the meeting Item 7 – Determination of the number of board members The shareholder Vega HoldCo Sarl, representing 28.61 per cent of the total number of outstanding shares in the Company, proposes that the number of board members in the Company shall continue to be five ordinary board members, with no deputies, as determined by the annual general meeting on 12 May 2016 (the “AGM”).   Item 8 – Determination of remuneration to the board of directors The shareholder Vega HoldCo Sarl, representing 28.61 per cent of the total number of outstanding shares in the Company, proposes that the remuneration to the board of directors in the Company shall continue to be the remuneration that was determined by the AGM, except that the chairman shall not receive any remuneration for the assignment as board member and chairman from the date of this extraordinary general meeting (the “EGM”). Remuneration between appointed and resigned board members shall be allocated pro rata in relation to the time they have served as board members. The proposal means that Knut Pousette (i) for the period as chairman, i.e. from the AGM until the day of the EGM, shall receive remuneration equal to the amount determined by the AGM for the chairman (calculated pro rata for the period) and (ii) for the period from the day of the EGM until the end of the next annual general meeting, shall receive remuneration equal to the amount determined for the other board members (calculated pro rata for the period). The resolution is conditional upon the EGM resolving in accordance with the proposal in item 9. Items 9 – Election of board members and chairman The shareholder Vega HoldCo Sarl, representing 28.61 per cent of the total number of outstanding shares in the Company, proposes that: -       Andrew Lax and Svein Erik Lilleland replace the board members Ranny Davidoff and Terje Nesbakken, who have requested to be replaced as board members, for the period until the end of the next annual general meeting; and -       Andrew Lax replaces Knut Pousette as chairman of the board of directors, for the period until the end of the next annual general meeting. _____________________  Right to require information and the nomination committee’s motivated statement The shareholders are reminded of their right to require information in accordance with Chapter 7 Section 32 of the Swedish Companies Act. Vega HoldCo Sarl has informed the nomination committee about the above proposals and their motivated statement regarding item 9 will be available for inspection at the Company’s offices, Strandvägen 5A, SE-114 51 Stockholm and on the Company’s webpage www.dcarnegie.se, at the latest on 23 September 2016, and will be sent to shareholders who so request and state their address. _____________________  Stockholm, September 2016 D. Carnegie & Co AB (publ) The board of directors

Bravida acquires Nilssons Elektriska AB in Kristianstad

Nilssons Elektriska primarily offers electrical installations and servicing, but the operations also include white goods, washing equipment, security systems and entry control. Among the customers are local property owners, building companies, industries and retail. – This acquisition will strengthen our market position in Kristianstad and north-western Skåne, says Anders Ahlquist, Head of Division, Bravida Division South. Nilssons Elektriska is a family-owned business, which for the past thirty years has been run by the sons of the founder. – The time has arrived for the next step in the company’s development. We have built our operations on long-term relationships, so it was important to us to sell to a company that shares our values, says Lars Nilsson, CEO of Nilssons Elektriska. Mats Karlsson, Regional Manager, Bravida Prenad, is pleased with the addition. – It feels great to be entrusted to continue the development of a company with such fine old traditions. Nilssons Elektriska has been active since 1949 and has very strong local hold. This will be a valuable addition in our region and it will give us new opportunities, says Mats Karlsson. Bravida will enter as the new owner on 1 November 2016. For further information, please contact:Mattias Johansson, CEO and Group President, Bravida. Phone: +46-8-695 20 00Lars Nilsson, CEO Nilssons Elektriska. Phone: +46-44-28 26 03Mats Karlsson, Regional Manager, Bravida Prenad. Phone: +46-42-16 74 01

HiQ HELPS ELENIA TO RESHAPE CUSTOMER SERVICE

”At Elenia we are constantly working to improve our customer satisfaction. As our business and services become more and more digital, integration plays an important role. Seamless connections between systems, processes and people’s work enables us to serve our customers even better,” says Jukka Grönroos, IT Manager at Elenia. HiQ has contributed with expertise and implemented an integration environment based on the FRENDS platform. The integration project was a central part in a large-scale project around customer relationship management in the Elenia Group. ”Instead of implementing only a technical solution, we aimed to build a partnership in which we could develop our integration environment together. HiQ provided us with the needed know-how in all phases of the project, on a technical as well as operational level,” Grönroos continues. Elenia builds power grids and information systems into a single smart grid that generates real-time data. The customers can receive information about their energy consumption on hourly, daily or monthly basis. ”Concepts such as IoT, remote monitoring and digitalisation have been common in the energy sector for years – the area is constantly looking for new and innovative ways to create value. HiQ has vast experience in creating digital services and automating business processes, and we are experts on integration. In April, HiQ was even recognized (http://news.cision.com/hiq-international/r/hiq-recognized-in-the-gartner-market-guide,c2015102) in the Market Guide for Hybrid Integration Platform-Enabling Technologies by Gartner, Inc - the world's leading IT research and advisory company,” says Jukka Rautio, Managing Director at HiQ Finland. ”In today’s tech-intensive and connected society we have little room for failures in power supply or customer service. We strive for simplicity and we are proud of this partnership with Elenia – a company that just like HiQ wants to make people’s everyday lives simpler and better,” says Lars Stugemo, President and CEO at HiQ. For more information, please contact: Jukka Rautio, Managing Director, HiQ Finland, Tel. +358 40 827 1142 Jenny Sperens, Head of Communications, HiQ, Tel. +46 734 431 007

Pandox AB (publ) acquires Hilton Grand Place Brussels for MEUR 55

“The acquisition of Hilton Grand Place Brussels is industrially sound and offers good potential. The hotel is strategically located adjacent to the Grand Place in Brussels with direct access to the central station, and benefits from both business and leisure demand. Based on its location, product, brand and meeting offering the hotel has good prospects to further gain market shares. The hotel property adds a distinct value to Pandox’s hotel portfolio in the continued development of the hotel market in Brussels”, says Anders Nissen, CEO of Pandox. The acquisition of the hotel property is made in a company owned by a private investor with an underlying property value of MEUR 55. In addition, MEUR 3 will be invested in room upgrades during 2017-2018. The total investment corresponds to a yield of more than 6 percent. The hotel has 224 rooms, 17 conference rooms and a complete F&B offering and is currently operated under a management contract with Hilton, which can be converted to a franchise agreement 2019. FOR MORE INFORMATION, PLEASE CONTACT: Anders Nissen, CEO, +46 (0) 708 46 02 02Liia Nõu, CFO, +46 (0) 702 37 44 04Anders Berg, Head of Communications and Investor Relations, +46 (0) 760 95 19 40 This information is information that Pandox AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, 21 September 2016, 08:00 CEST. About PandoxPandox is a leading owner of hotel properties in Northern Europe with a focus on sizeable hotels in key leisure and corporate destinations. Pandox’s hotel property portfolio comprises 112 hotels with more than 24,000 hotel rooms in eight countries. Pandox’s business is organised into Property Management, which comprises hotel properties leased on a long-term basis to market leading regional hotel operators and leading international hotel operators, and Operator Activities, which comprises hotel operations executed by Pandox in its owner-occupied hotel properties. Pandox was founded in 1995 and the company’s B shares are, as of 18 June 2015, listed on Nasdaq Stockholm. www.pandox.se

Elocta® obtains reimbursement in UK, Italy and France, complemented by real-world data and extensive patient experience

Patient access to Elocta is increasing, contributing to further evidence generation and real-world patient experience for extended half-life factor VIII therapy Swedish Orphan Biovitrum AB (publ) (Sobi™) (http://www.sobi.com/) today announces that the company’s product Elocta® (efmoroctocog alfa), a recombinant human factor VIII Fc-fusion protein with an extended half-life for the treatment of haemophilia A, has been approved for  reimbursement in the UK, Italy and France. These countries join Germany, Sweden, Denmark, Norway, Switzerland, the Netherlands, Slovenia and the Republic of Ireland where Elocta is already available. This expansion in availability is supported by global experience. With more than two years of post-authorisation real-world experience with Elocta (marketed as Eloctate® in the US and other regions), over 2,700 patients have been treated in countries where Elocta is commercially available, corresponding to about 1,800 patient-years of experience.   “This extensive post approval clinical experience with Elocta complements the clinical data generated by our pivotal clinical studies, and follows the findings of the long term ASPIRE extension study. We believe that this comprehensive clinical data and real world experience can provide support to clinicians and patients while making their treatment choices as Elocta becomes available in additional countries,” said Krassimir Mitchev, MD, PhD, Vice President and medical therapeutic area head of Haemophilia at Sobi. The safety and efficacy of long-term use of the extended half-life recombinant Fc-factor VIII, Elocta for haemophilia A were highlighted in a series of oral and poster presentations by Biogen and Sobi at the World Federation of Hemophilia (WFH) 2016 World Congress in Orlando, Florida that took place 24-28 July 2016. Through the pivotal clinical trials (A-LONG, Kids A-LONG) and extension study (ASPIRE) 233 patients have been treated with Elocta. Overall clinical study experience with Elocta confirms its long term safety and efficacy, and supports its potential to offer extended protection against bleeds. Eloctate was first approved for haemophilia A in the USA in June 2014 and in the EU (as Elocta) in November 2015. ------------ About Haemophilia AHaemophilia is a rare, genetic disorder in which the ability of a person's blood to clot is impaired. Haemophilia A occurs in about one in 5,000 male births annually, and more rarely in females.   People with haemophilia A experience prolonged bleeding episodes that can cause pain, irreversible joint damage and life-threatening haemorrhages. Prophylactic infusions of factor VIII can temporarily replace the missing clotting factors that are needed to control bleeding and prevent new bleeding episodes.[i] (http://teamsites.sobi.com/s/corporate-communications/Shared%20Documents/Press%20releases/041_WFH%20real%20world%20data/041e_TAH%20real%20world%20experience_final.docx#_edn1) The World Federation of Hemophilia recommends prophylaxis as the optimal therapy as it can prevent bleedings and joint destruction.[ii] (http://teamsites.sobi.com/s/corporate-communications/Shared%20Documents/Press%20releases/041_WFH%20real%20world%20data/041e_TAH%20real%20world%20experience_final.docx#_edn2) About Elocta®/Eloctate®Elocta (efmoroctocog alfa), the first recombinant clotting factor VIII therapy that offers an extended half-life in the body, is approved in the European Union, Switzerland, Iceland, Liechtenstein and Norway, as well as the United States, Canada, Australia, New Zealand and Japan (as Eloctate). It was developed for haemophilia A by fusing factor VIII to the Fc portion of immunoglobulin G subclass 1, or IgG1 (a protein commonly found in the body). This enables Elocta to use a naturally occurring pathway to prolong the time the therapy remains in the body. While Fc fusion technology has been used for more than 15 years, Sobi and Biogen are the first companies to utilise it in the treatment of haemophilia. As with any factor replacement therapy, development of inhibitors may occur following administration of Elocta/Eloctate. About Sobi™Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi’s mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. Sobi also markets a portfolio of specialty and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 385 M) and about 700 employees. The share (STO: SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com. For more information please contact: Media relations  Investor relations Linda Holmström, Jörgen Winroth, ViceExternal Communications President, Head of InvestorManager RelationsT: + 46 708 73 40 95, + T: +1 347-224-0819, +1 21246 8 697 31 74    -579-0506, +46 8 697 2135linda.holmstrom@sobi.com  jorgen.winroth@sobi.com          ---------------------------------------------------------------------- [i] (http://teamsites.sobi.com/s/corporate-communications/Shared%20Documents/Press%20releases/041_WFH%20real%20world%20data/041e_TAH%20real%20world%20experience_final.docx#_ednref1) World Federation of Hemophilia. About Bleeding Disorders – Frequently Asked Questions. Available at: http://www.wfh.org/en/page.aspx?pid=637#Difference_A_B. Accessed on: June 17, 2016. [ii] (http://teamsites.sobi.com/s/corporate-communications/Shared%20Documents/Press%20releases/041_WFH%20real%20world%20data/041e_TAH%20real%20world%20experience_final.docx#_ednref2) Guideline for the management of hemophilia, World Federation of Hemophilia, 2nd edition, http://www1.wfh.org/publication/files/pdf-1472.pdf. Accessed December 2015 (http://www1.wfh.org/publication/files/pdf-1472.pdf.%20Accessed%20December%202015) 

Eniro changes its Group Management Team; Board of Directors to evaluate ownership of some parts of the Group

Today, the Eniro Group has announced a number of changes to its Group Management Team. The changes will strengthen Eniro’s sales efforts and increase focus on developing the company’s future customer offering, as well as establishing a slimmer, more dynamic Group Management Team. New customer offering“During the last few months, we have worked intensively with the creation of Eniro’s future business proposition. In consequence, Eniro will introduce two new strong concepts to the Swedish market this fall. We operate in an extremely fragmented market where many players are competing for the local SME customers, making it quite difficult and challenging to be an advertiser today. We will meet our customers’ needs with simple, easy-to-use solutions tailored to deliver the correct marketing mix for the customer, once again proving that Eniro is where SMEs can go to get help with their local marketing,” says CEO Örjan Frid. New Head of SalesTo strengthen the sales effort, including the introduction of Eniro’s new customer offering to the market, Mattias Wedar has been appointed acting Head of Nordic Sales. Mattias was previously Head of User & Customer Experience and has held several management positions at Eniro since 2008. “We make this change to get a fresh perspective on our sales effort. Mattias has prior experience with managing the sales forces in both Sweden, Norway and Denmark, and I’m fully confident that he will bring new ideas to the table that will get us back on track,” says Örjan Frid. New Group Management TeamCEO Örjan Frid has chosen to step in as acting Head of User & Customer Experience himself. “We’re currently working hard to develop a much needed update to Eniro’s customer offering. To be able to offer a modernized, improved product portfolio is a top priority right now, and I have chosen to step in as acting Head of User & Customer Experience until the work is completed,” says Örjan Frid. Following these changes, Eniro’s Group Management Team is constituted by CEO Örjan Frid, CFO Fredrik Sandelin, and Head of Nordic Sales Mattias Wedar. Strategic review of Group structure and capital structureAlong with the clarification of the new customer offering, the Eniro Board of Directors is making a strategic review regarding the ownership of some of the Group holdings. In addition, the Board of Directors is addressing the capital structure of the Group.

Nomination Committee of Avanza Bank Holding AB

At the 2016 Annual General Meeting of Avanza Bank Holding AB (publ) it was decided that the Nomination Committee should be formed not later than six months before the 2017 Annual General Meeting. The committee’s members would include one representative for each of the four shareholders controlling the largest number of votes, together with Avanza Bank Holding AB’s Chairman of the Board. The four shareholders controlling the largest number of votes, and who wish to appoint a representative are, according to Avanza Bank Holding AB’s knowledge: Creades AB, Sven Hagströmer with family and companies, the Dybeck family and companies and Didner & Gerge Fonder. These shareholders have decided that the Nomination Committee shall consist of the Chairman of the Board Sven Hagströmer, Erik Törnberg representing Creades AB, Sten Dybeck representing the Dybeck family and companies and Henrik Didner representing Didner & Gerge Fonder. Erik Törnberg has been appointed Chairman of the Nomination Committee. Proposals to the Nomination Committee may be sent by e-mail to:valberedningen@avanza.se Or by ordinary mail to:Avanza Bank Holding ABAtt: ValberedningenBox 1399111 93 Stockholm, Sweden “This information is such that Avanza Bank Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person set out below, at 08:15 CEST on 21 September 2016.”

Notice of extraordinary general meeting of D. Carnegie & Co AB (publ)

The shareholders of D. Carnegie & Co AB (publ) (the “Company”) are hereby summoned to an extraordinary general meeting on Friday 14 October 2016 at 2 p.m. at Advokatfirman Vinge’s office at Smålandsgatan 20, in Stockholm. The extraordinary meeting is summoned further to the shareholder Vega HoldCo Sarl, a company controlled by Blackstone, representing 28.61 per cent of the total number of outstanding shares in the Company, having requested an extraordinary general meeting in order to resolve on election of board members, election of chairman and remuneration to the board of directors in the Company. Right to attend the general meeting Shareholders who wish to attend the general meeting must be registered in the share register maintained by Euroclear Sweden AB on Friday 7 October 2016, and must also notify the Company of their intention to attend the meeting no later than Monday 10 October 2016. The notification must be made in writing to D. Carnegie & Co AB (publ), Strandvägen 5A, SE-114 51 Stockholm or by e-mail to info@dcarnegie.se. The notification must state the shareholder’s name, personal identity number/registration number, shareholding, address, day time telephone number and information about the attendance of any assistants (maximum two) and, if applicable, information about any proxies. Proxy Shareholders represented by proxy must submit a dated power of attorney. If the power of attorney is executed by a legal person a certified copy of the certificate of registration or equivalent should be attached. The power of attorney and the certificate of registration may not be older than one year, however, the power of attorney may be older provided that the power of attorney according to its wording is valid for a longer period, although, not more than five years. The original power of attorney and the certificate of registration should be sent to the Company at the address mentioned above in good time prior to the general meeting. A proxy form is available at www.dcarnegie.se and will also be sent to shareholders who so and state their postal address.  Nominee-registered shares Shareholders whose shares are registered in the name of a nominee through a bank or a securities institution must temporarily re-register their shares in their own names in order to be entitled to attend the general meeting. Such registration must be duly effected in the share register maintained by Euroclear Sweden AB on Friday 7 October 2016, and the shareholders must therefore advise their nominees well in advance of this date. Number of shares and votes In the Company, on the day of this notice, there are a total of 5,369,866 shares of series A that hold five (5) votes per share at the general meeting and 71,938,910 shares of series B that hold one (1) vote per share at the general meeting. Thus, there are a total of 77,308,776 shares and 98,788,240 votes in the Company. Proposed agenda 1.                 Opening of the meeting2.                 Appointment of chairman of the general meeting3.                 Preparation and approval of the voting list4.                 Approval of the agenda5.                 Election of one or two persons to approve the minutes6.                 Determination of whether the general meeting has been duly convened7.                 Determination of the number of board members8.                 Determination of remuneration to the board of directors9.                 Election of board members and chairman10.              Closing of the meeting Item 7 – Determination of the number of board members The shareholder Vega HoldCo Sarl, representing 28.61 per cent of the total number of outstanding shares in the Company, proposes that the number of board members in the Company shall continue to be five ordinary board members, with no deputies, as determined by the annual general meeting on 12 May 2016 (the “AGM”).   Item 8 – Determination of remuneration to the board of directors The shareholder Vega HoldCo Sarl, representing 28.61 per cent of the total number of outstanding shares in the Company, proposes that the remuneration to the board of directors in the Company shall continue to be the remuneration that was determined by the AGM, except that the chairman shall not receive any remuneration for the assignment as board member and chairman from the date of this extraordinary general meeting (the “EGM”). Remuneration between appointed and resigned board members shall be allocated pro rata in relation to the time they have served as board members. The proposal means that Knut Pousette (i) for the period as chairman, i.e. from the AGM until the day of the EGM, shall receive remuneration equal to the amount determined by the AGM for the chairman (calculated pro rata for the period) and (ii) for the period from the day of the EGM until the end of the next annual general meeting, shall receive remuneration equal to the amount determined for the other board members (calculated pro rata for the period). The resolution is conditional upon the EGM resolving in accordance with the proposal in item 9. Items 9 – Election of board members and chairman The shareholder Vega HoldCo Sarl, representing 28.61 per cent of the total number of outstanding shares in the Company, proposes that: -       Andrew Lax and Svein Erik Lilleland replace the board members Ranny Davidoff and Terje Nesbakken, who have requested to be replaced as board members, for the period until the end of the next annual general meeting; and -       Andrew Lax replaces Knut Pousette as chairman of the board of directors, for the period until the end of the next annual general meeting. _____________________  Right to require information and the nomination committee’s motivated statement The shareholders are reminded of their right to require information in accordance with Chapter 7 Section 32 of the Swedish Companies Act. Vega HoldCo Sarl has informed the nomination committee about the above proposals and their motivated statement regarding item 9 will be available for inspection at the Company’s offices, Strandvägen 5A, SE-114 51 Stockholm and on the Company’s webpage www.dcarnegie.se, at the latest on 23 September 2016, and will be sent to shareholders who so request and state their address. _____________________  Stockholm, September 2016 D. Carnegie & Co AB (publ) The board of directors

Nordic Paper goes pink

By selling a ton of sheeted Greasproof paper through an action where the buyer can place their bids, Nordic Paper is supporting the campaign Pink Ribbon.The selling amount for this ton will go directly to Cancer Foundation and their Pink Ribbon Campaign.  Once a week we will update our social media with the company name that has offered the highest bid. The auction will start 1th of October and end the last of October.  The sheeted paper is of course a Natural Greaseproof paper and the only difference between the ordinary paper that we usually sell and this auctioned paper is that this ton is delivered in pink boxes. And of course the fact that the selling amount is donated to Cancer Foundation and Pink Ribbon. This means that the buyer also contributes to the cancer research! Pink Ribbon campaign is held every year and the purpose is to finance cancer research , but also to support breast cancer pations, survivors and their families all over the world. It´s an internationally operationg charity organization aimed to create a global community for these purposes. Nordic Paper is an international company that manufactures both Greaseproof paper and Kraft Paper. We are among the biggest manufacturers in the wold and we want to be a part of the amazing work that colors, not only Sweden, but hopefullly most of the world pink during a mont due to a good cause.Therefore we really hope that a lot of people and companies around us becomes a part of this! - The design of the pink boxes is specially developed by a Swedish designer, Maria K Back at Whiter Shade, for this campaign and we really hope that there will be a lot of buyers that place their bids since we are sending the selling amount directly to the Pink Ribbon , says Marie Stenquist, Corporate Communications/PR manager at Nordic Paper.

Scania’s application-focused solutions:Optimised customer profitability is Scania’s goal

With the introduction of our new truck generation, we’re placing an even greater focus on the opportunities for connected European customers to earn money through their investment in solutions from Scania,” says Christopher Podgorski, Senior Global Vice President, Scania Trucks. “Our focus on applications, integrated solutions, modularisation, and user-based data make us the industry leader. With help from these tools, our salespeople – in dialogue with customers – can tailor optimised solutions with the potential for optimal profitability for all types of driving assignments.” Scania views every truck as a production unit – the better suited it is to its unique duties and the more supported it is by tailor-made services, the bigger the haulage company’s potential to get a return on its investment. The haulier’s results are affected by a range of factors. Some of them are relatively simple to identify and influence. Others are controlled by circumstances beyond their own control or seem insignificant at first glance, despite the fact that over time they can have a major influence on both costs and revenue. “We have the insights and experience needed to create optimised solutions,” says Podgorski. “Because Scania also has access to crucial information such as actual operational data from real vehicles, our way of working gives powerful leverage to our customers in the form of optimised solutions that take in everything from usage-based maintenance, to finance and insurance. The effects of digitalisation The ongoing shift to digitalisation and the steady increase in access to decision-making data – including operational and performance data – means that Scania can be proactive and innovative. From an ocean of information, Scania chooses and analyses relevant data for each application and driving activity. “We are fast entering a world where services and smart management of information form the basis of profitability,” says Podgorski. “Many in the transport industry are still working with a strict focus on costs, with the  vehicle’s purchase price a typical factor. In cases like this, it’s important to remember that things such as earning ability – which is largely controlled by how optimised the vehicle is for its particular duties – have a far greater impact on whether there’s a profit or a loss for the business.” A good example of the way that Scania uses its accumulated knowledge is the newly developed sales support system. It distills the company’s collective knowledge regarding trucks, optimised transport solutions, and industry conditions as well as actual customer needs for different applications. This work tool is the result of many years’ work involving collating, analysing and spreading Scania’s significant know-how regarding the multifaceted truck and transport industry. Scania was one of the pioneers of connecting all vehicles for purposes such as optimising usage and availability. Scania has also been at the forefront of improving the process around getting bodywork in place on vehicles. One key step was launching a site in the summer of 2016 with a focus on supporting body builders. Another decisive step was Scania switching to CAN-bus technology, which greatly improves the potential for configuring and controlling body building and related functions. ”We are working constantly to improve the outlook for customers,” says Podgorski. “Access to real-time data is extremely hot right now, as it means you no longer have to guess when it comes to the vehicle’s position, its maintenance needs, or its actual fuel consumption. In short, a partnership with Scania means that haulage operators are better placed than ever before to improve profitability.” Flexible maintenance plans One of the best examples of this is Scania Maintenance with Flexible Plans, a service that was initially offered across the whole of Europe a bit more than a year ago. That process is almost complete now that the new generation of trucks has been introduced. With all new trucks connected, the basis for the service is how these vehicles are used – and not the traditional mileage counts or calendar-based approaches – controls how they should be serviced under the maintenance contract that Scania and the customer draw up together. “Scania Maintenance with Flexible Plans is the latest and the main contribution to the ecosystem of services – both physical and digital – that we offer and which is crucial to being able to operate businesses that are sustainable in the long-term,” says Podgorski. ”Being able to tailor complete and individual solutions, including things like service and financing, is crucial in our industry. It's here that the conditions for either profit or loss are created in the only operation the customer really cares about – their own.” For more information, please contact: Örjan Åslund, Head of Product Affairs, Scania Trucks,+46 70 289 83 78, orjan.aslund@scania.com

Court Ruling Quashes Industry Move to Undermine EU Ban on New Animal Test Data for Cosmetics

LONDON (21 September 2016) – The Court of Justice of the European Union has confirmed the EU’s 2013 ban on cosmetic animal testing and trade with a verdict today that expressly forbids companies from relying on results from animal tests conducted outside of the EU after March 2013 to substantiate the safety of cosmetic products in the EU. Humane Society International welcomes the ruling as a win for animal welfare advocates. The European Federation for Cosmetics Ingredients brought the case seeking a narrower interpretation of the ban by the court, under which new animal tests conducted under legislation in non-EU countries could be used to substantiate the safety of cosmetics under EU law. Such a narrow interpretation would have rendered the EU ban toothless.   “We are pleased that this cynical attempt by the industry to circumvent the EU’s restrictions on cosmetics animal testing and sales has failed,” said HSI #BeCrueltyFree campaign director Claire Mansfield. “The court’s ruling does justice to clear consumer demand for an end to cruel cosmetics, and reinforces the ongoing work of Humane Society International’s global #BeCrueltyFree campaign to extend the EU’s precedent-setting bans on cosmetics animal testing and trade to all major beauty markets. With this positive momentum we may be only a few years away from a world where cosmetics companies will have to go cruelty-free to remain profitable.” Humane Society International was a major player in convincing the EU to implement its 2013 sales ban on newly animal-tested cosmetic products and ingredients, and together with regional #BeCrueltyFree campaign partners was the leading force behind the adoption of similar bans in India, New Zealand and South Korea. #BeCrueltyFree campaign teams are currently working with the United States, Canada, Australia, Brazil, Taiwan and other nations to enact additional air-tight bans.    - 30 - Media contacts: · Europe: Susie Wilks, swilks@hsi.org, +44 7900 953507 · North America: Raúl Arce-Contreras, rcontreras@humanesociety.org, +1 301-721-6440

Citycon decided on a quarterly distribution

The Board of Directors of Citycon Oyj has today decided that an equity repayment of EUR 0.0375 per share be distributed from the invested unrestricted equity fund of the company. The equity repayment will be paid to a shareholder registered in the company’s shareholders’ register maintained by Euroclear Finland Ltd on the record date for the equity repayment September 23, 2016. The equity repayment will be paid on September 30, 2016. The distribution is based on the authorization by Citycon Oyj’s Annual General Meeting held on March 16, 2016. The total amount of the authorization shall not exceed EUR 0.1125 per share and the authorization is valid until the opening of the Annual General Meeting 2017. Following the equity repayment on September 30, 2016, Citycon Oyj has distributed a total dividend and equity repayment of EUR 0.1125 per share during the year 2016. The remaining authorization of the Board of Directors is EUR 0.0375 per share. Helsinki, September 21, 2016CITYCON OYJ For further information, please contact:Marcel Kokkeel, CEOTel. +358 40 154 6760marcel.kokkeel@citycon.com Eero Sihvonen, Executive Vice President and CFOTel. +358 50 557 9137eero.sihvonen@citycon.com Citycon Oyj (Nasdaq Helsinki: CTY1S) is a leading owner, developer and manager of urban grocery-anchored shopping centres in the Nordic and Baltic regions, managing assets that total EUR 4.7 billion and with market capitalisation of close to EUR 2 billion. For more information about Citycon, please visit www.citycon.com

Haldex at IAA: World debut of the lightest disc brake on the market

At the top of the current range is the heavy-duty version of the 22.5-inch model with a maximum brake torque of 30 kNm. At the show, the DBT 22 MD model for trucks and buses will have its world debut. It has a maximum brake torque of 25 kNm and a weight of just 34 kg with pads, which is several kg lighter than comparable models from competitors. The DBT 22 LT ModulT for trailers and semi-trailers is presented in a new version that is even slimmer and now weighs less than 30 kg with pads, which definitely is the lightest 22.5-inch disc brake for trailers on the market. Also appearing in Hanover will be the DBT 19 LT trailer brake with a maximum brake torque of 18 kNm. “Haldex is entering into a new era for disc brakes with the 22-inch model for trucks. We have been demonstrating this model to selected customers since the spring with very positive response. Now it’s presented for a larger audience at the IAA show.”, says Bo Annvik, President & CEO of Haldex. “Haldex is known for its lightweight disc brakes for trailers which is our fastest growing product line. We plan to repeat the same successful growth story in the truck segment as we have done in the trailer segment in Europe. With the technology shift in North America from drum brakes to disc brakes, we are well positioned with our current disc brake offering when the technology shift is taking place in North America.”     “We’re very proud to present the lightest disc brake range on the market. Weight optimization is creating sustainable solutions with lower fuel consumption which is key when designing the commercial vehicles of the future.” said Jeff Stokes, Global Product Manager – Disc Brakes for Haldex. “The ModulT air disc brake is the perfect solution for customers looking for high efficiency with greater control and stability for a long service life with lower total cost of ownership,” All ModulT brakes utilize Haldex's special single-tappet mechanism, which offers two key benefits. The first is extensive support and uniform pressure on the brake pads. The second is a weight-optimized design that is not a single gram heavier than necessary. It was not just the single-tappet design that reduced the weight of the ModulT: All parts, and the calliper, in particular, have undergone intensive finite element analysis. The result is a new and especially slim yet stronger architecture. The 19.5-inch and 22.5-inch versions have also raised the standard in their classes for maintenance and repair. With the new design, engineers have minimized the number of parts subject to wear. Another advantage is exceptionally uniform wear of the inner and outer pads thanks to particularly well-balanced clamping force distribution, which prevents heat cracks and uneven wear while also contributing to excellent braking power. In addition, double roller bearings in the lever mechanism guarantee low hysteresis and great efficiency. The brake is well-protected from potentially damaging external forces: The calliper guide of the ModulT disc brake is completely enclosed, and thanks to the inverted mechanism bellows, the brake is well-protected, which makes the mechanism far less subject to damage from dirt and stirred-up solids.

Scania’s new truck generation honoured – The S series elected “International Truck of the Year 2017”

“The award is the leading recognition in the industry that all our engineers and in practice the entire Scania organisation have done an excellent job,” says Henrik Henriksson, Scania’s President and CEO. “Our goal is to always meet our customers’ expectations and needs and the jury’s motivation is a clear confirmation that we have also followed the right approach with the new truck generation.” The jury, which is today composed of 25 leading European trade press journalists and chaired by the Italian automotive journalist Gianenrico Griffini, wrote the following in its motivation: “With its new range, Scania has delivered a truck that represents a real “state-of-the-art” offering in the heavy duty segment, capable of satisfying not only today’s but also tomorrow’s transport needs.” The IToY jury also highlighted Scania’s tailored service offering, which is based on the fact that more than 200,000 connected Scania vehicles are out on the roads.       The award is for the S series − the new sleeper cab with a flat floor that is mainly intended for long-haulage trucks and that Scania has just introduced within the framework of its new truck generation. “The S cab, with its flat floor, offers a truly car-like driving experience,” says Griffini. Besides offering exceptional comfort and unrivalled space, the S cabs can also be fitted out with dual side curtain airbags, a safety feature, which Scania is the first in the truck world to be able to offer. “The new truck generation, which will be honoured was developed by our 3,500 engineers in Södertälje together with other Scania employees and in close dialogue with our customers,” says Henriksson. “The award shows that Sweden is still a leading industrial nation and that we can compete in the world markets.”     Scania’s investment in the model range is the largest ever in the company’s 125-year history. In total, SEK 20 billion has been invested in the development of new products and services, including in the adjustment of production. For further information, please contact Örjan Åslund, Head of Product Affairs, Scania Trucks, Tel. +46 70 289 8378, e-mail orjan.aslund@scania.com

Bonava sells 96 rental apartments in Germany

- The development of high-quality, affordable rental units is important to realizing our vision of creating homes and happy neighborhoods where people have the highest quality of life, says Joachim Hallengren, President and CEO of Bonava. This is not Bonava’s first project in the area. Bonava, which according to the independent market research company BulwienGesa is the most active residential development company in Germany’s metropolitan areas, has purchased a total of 115 000 m2 of land and sold 85 new row houses to private customers, and this new residential area is already home to 43 families. The sale will be the sixth of its kind to Industria Wohnen. The housing project is expected to be completed and will be recognized in profit in Bonava Germany in the fourth quarter of 2017. For more information, please contact: Ann-Sofi Danielsson, CFO and Head of Investor Relationsann-sofi.danielsson@bonava.comTel: +46 706 740 720 Bonava’s media line: +46 700 887 133, E-mail: ir@bonava.com Bonava is a leading residential development company in Northern Europe. Born out of NCC, Bonava has been creating homes and neighbourhoods since the 1930’s. Today Bonava has 1,400 employees and operates in Sweden, Finland, Denmark, Norway, Germany, St. Petersburg, Estonia and Latvia with sales of SEK 13 billion. Bonava’s shares are listed on Nasdaq Stockholm. For more information about us:  bonava.com (http://www.bonava.com/)

LICOS Trucktec GmbH in a new outfit; more than just a design change?

LICOS is a well-known brand in the truck industry. What was the driver to change the logo? The company, founded in 1998 by Dr. Andreas Wolf and Karl-Heinz Linnig, was acquired by Concentric AB in 2013. Changing the logo into Concentric’s corporate colours was the final step of the successful integration of LICOS into the wider Concentric group. We´ve changed the colours but we have not changed the brand name or the products. Our name stands for high-quality and innovative products. To date we have delivered over half a million clutches into the EURO5 and EURO6 engines of Europe’s top truck brands.  The clutches save a huge amount of diesel and we have a calculation ticker on our homepage www.licostrucktec.com where you can find the total of saved litres of diesel. Concentric AB is listed on the Swedish stock exchange and, prior to the acquisition in 2013, LICOS was just a typical German midsize company. This July you celebrated the 3rd anniversary of joining the Concentric group. What have been the major changes for the Company since 2013? I think the changes that we have seen were not that dramatic. Yes, for sure, there is a big difference if you have to change your internal reporting system from a German family owned company into a member of an international listed group. On the other hand, LICOS already had international quality standards and customers before the change of ownership. Our customer rating has been excellent since the inception of the Company so there were no changes necessary on that side of the business. What were the customer reactions following the change in ownership? Our customers have been informed and were visited by our management team shortly after the shareholder change. Their reaction was generally very positive and may be best summed up by the following statement from a senior level manager at one particular customer: “The LICOS clutch is a major component for the EURO6 engine. It is good to know that the company now belongs to a bigger group with a global footprint.” In times of globalization, it is important to have local manufacturing and applications support located right next to the assembly plants of the global truck manufacturers. What are the plans for the future of LICOS in this global truck business? Do you have new technologies or products to add to your current portfolio? The current business of LICOS is secured by our patent protected 2 speed clutch technology, which we sell currently only to the European market. Our sales team is working hard with customers in North America and Asia to introduce the 2 speed clutch technology into these markets as soon as possible. In addition, we expect to launch the production of our double cone clutch in the near future. This clutch is our new technology for switching high torque in very limited space. The technology is developed by LICOS and is fully patent protected. All the tests to date have been positive and the customers are very interested to get this technology onto their engines as soon as possible.  Our passion is to develop products which help make the truck more efficient and the double cone clutch is another example of LICOS providing a high tech and robust solution for our customers. Concentric AB is an innovator in flow control and fluid power, supplying proprietary systems and components to the world’s truck, construction, mining and agricultural equipment industries.  The Concentric group has manufacturing facilities in the UK, USA, Germany, Sweden, India, China and Argentina.

IK and Five Arrows complete the acquisition of I@D

Founded in 2008 with the ambition to offer an alternative way of buying and selling residential property, I@D is a fast-growing digital platform offering a large range of value-added support services to independent real estate agents. The Company has demonstrated a stellar track record of organic growth since inception and has grown to become the largest network in France with ca. 3,200 local agents and over 11,800 transactions intermediated last year. I@D posted revenues of ca. €80 million for fiscal year ending June 2016. “We are delighted to have the opportunity to contribute to the future success of I@D. We have been very impressed with the Company’s achievements so far and believe that I@D has tremendous growth potential with further market penetration in France, expansion of its real estate service offering and potential development in selected countries in Europe. We will support the management team in the implementation of its strategic plan, and aim to preserve the entrepreneurial spirit of the Company,” said Dan Soudry, Partner at IK and advisor to the IK VII Fund. “We are very proud to support I@D in the next stage of its development. We are looking forward to collaborating with the management team and helping the Company to further scale its operations in France and accelerate its recent international expansion,” said Emmanuel Roth, Co-Managing Partner at Five Arrows Principal Investments. “We are very pleased to welcome IK and Five Arrows who share our long term strategic vision for the business and plan to support our successful track record of delivering strong growth of the network domestically, as well as expand to adjacent segments or new geographies,” said Malik Benrejdal, CEO of I@D France. “Since 2012, we have appreciated the quality of the management and have recorded the relevance of I@D’s business model whose turnover has increased from €23m to €80m. We are convinced of the potential of development in France that is still high and of the success of the model’s duplication worldwide. That’s why NAXICAP Partners is very pleased to support I@D in this new project,” said Laurent Sallé, Managing Partner at NAXICAP Partners. Parties involved IK Investment Partners – Dan Soudry, Rémi Buttiaux, Vincent Elriz, Thibaut RichardFinancial advisor: goetzpartners (Guillaume Piette, Cedric Hawthorn, Adrien Hautefeuille, Julien Pascal, Leo Fallourd)Strategic DD: ATKearney (Jerome Souied, Hugo Azerad, Nicholas Veg, Charlotte Lescop)Financial DD: KPMG (Vincent Delmas, Stephanie Taupin, Maroua Bouchareb)Legal advisor: Willkie Farr & Gallagher (Eduardo Fernandez, Gregory De Saxce, Gil Kiener, Stanislas Curien, Mathilde de Wiljes)Debt financing: Permira (David Hirschmann, Roy Awad) Five Arrows Principal Investments – Emmanuel Roth, Nicolas Robin, Brahim Ammor, Stéphane GaudardFinancial advisor: UBS (Jerome Pin, Anne-Sophie Serre)Legal advisor: De Pardieu Brocas Maffei (Jean-François Pourdieu, Matthieu Candia) I@D France Founders – Malik Benrejdal, Jade Benrejdal, Jérôme ChabinNAXICAP Partners – Laurent Salle, Clemence RousseletFinancial advisor: Edmond de Rothschild Corporate Finance (M&A: Christophe Marchand, Inès Reinmann-Toper, Sebastien Auger, Sara Napolitano, Arthur Pignot; financing: Gregory Fradelizi, Paul O’Mahony)Strategic DD: Eleven (Ambroise Huret, Thomas Littee)Financial DD: Accuracy (Arnaud Lambert, Florence Westermann)Legal advisor: Pinot de Villechenon & Aassociés (Gilles Roux, Tristan Segonds)IT advisor: Octo Technology (Jean-Damien Blanc, Stephen Perin)Founders’ special advisor: Hoche Société d’Avocats (legal: Guillaume Martinet, Alexia Berbain Faguer; tax: Eric Ginter, Julien Bellet), Groupe Pictet (Paul Puech), Banque Privée 1818 (Pierre-Emmanuel Eveillard)

Tieto enters into strategic partnership with Lyse – strengthening foothold in Norway

The scope of the agreement is minimum M€30 over 5 years, with the last two years as optional. The key ambitions of the agreement is to reduce IT costs, optimize business processes and strengthen the Lyse Group’s ability to develop and deploy new services faster. Automation, speed and innovation are key elements to succeed in the digital world.  “Technology, and not least the users' expectations, are changing rapidly, and it imposes stricter requirements on our IT systems. We have to deal with upgrades, capacity expansion, new versions and increased requirements for robust security solutions. All this happens in a fierce pace. The partnership with Tieto enables faster innovation and flexibility, and facilitates cost control where we pay for actual consumption of services, says Eimund Nygaard, CEO of Lyse. Nygaard also emphasizes that Lyse is very satisfied that Tieto uses Green Mountain at Rennesøy as its Norwegian data centre.  The Lyse Group was established following the merger of several energy companies in 1998, being operational from 1999. Since then the company has transformed itself from a traditional power company with roots dating back to beginning of the 20th century into a group with several different business areas, including infrastructure, telecommunications and renewable energy, also delivering smart home and welfare technology solutions for customers across Norway.  “We are extremely proud to be selected to deliver on one of the most interesting IT challenges in the Nordics. Lyse is recognized as a leading national corporation with strong positions both in gas and hydro energy as well as pioneering solutions in telecommunications, home security and welfare technologies. As such Lyse has taken a unique position for further growth. We warmly welcome Lyse to our ecosystem,” says Christian Schøyen, country manager of Tieto Norway. According to the new agreement, Tieto will provide Lyse with a unified multi-cloud management platform and a true hybrid cloud that includes a set of dedicated private cloud services from Tieto’s Norwegian data centre combined with global public cloud solutions from leading suppliers. For more information:Kia Haring, Head of Global Communications: kia.haring[at]tieto.com, +358 40 765 3700Lars Rasdal, Communications Advisor, Lyse: +47 934 88 142 About LyseLyse is a Norwegian industrial group operating within the fields of energy and fibre-based broadband. The Group began operations on 1 January 1999 but has roots that extend more than 100 years back in time. The Group is owned by 16 municipalities in Sør-Rogaland. 100 years ago forward-looking thoughts led to the acquisition of waterfall rights, as well as the construction of a hydroelectric power plant and the network of lines that have benefited an entire region. The Lyse Group has developed into a substantial national operator within renewable energy. With experience from building and operating infrastructure, the Group has established itself as the national leader within fibre-optic broadband. In recent years Lyse has developed a gas network in Sør-Rogaland and operates an LNG business in a Nordic market. www.lyse.no   Tieto aims to capture the significant opportunities of the data-driven world and turn them into lifelong value for people, business and society. We aim to be customers’ first choice for business renewal by combining our software and services capabilities with a strong drive for co-innovation and ecosystems. www.tieto.com

Saab to provide shipboard air traffic radar systems for U.S. Navy

The radar will be deployed to the US Navy’s Aircraft Carrier (CVN)and Amphibious Assault (LH)Class ships, replacing the currently deployed AN/SPN-43C Air Traffic Radar. The SPN-50 system supports the deployment, sustainment and operation of aviation assets by providing aircraft position, radar signal, and weather data. Air traffic controllers use this data for air traffic control services, such as aircraft sequencing and separation, airspace identification and containment, safety alerts, traffic advisories, and landing guidance. “The U.S. Navy is increasingly called upon to support missions involving manned and unmanned aviation operations. With the SPN-50, air traffic controllers can support joint coalition forces across the full range of military operations in all weather conditions,” says Erik Smith, President and CEO of Saab Defense and Security USA. Saab is a world leader in air traffic management as well as in military radar and sensor technology. The SPN-50 program allows Saab to leverage its knowledge, skills and capabilities from both domains. “Saab’s naval radars are a proven success with the U.S. Navy. Our AN/SPS-77 radar is currently deployed aboard the Navy’s Independence-class Littoral Combat Ship and we look forward to a continued partnership with the new SPN-50 program,” continues Mr. Smith. The AN/SPN-50 system acquisition, deployment and sustainment is managed by Naval Air Systems Command’s Naval Air Traffic Management Systems Program Office. The office is the Naval Aviation Enterprise’s Program Office for all Navy and Marine Corps Air Traffic Management Systems. For further information, please contact: Saab Press Centre, +46 (0)734 180 018, presscentre@saabgroup.com www.saabgroup.com www.saabgroup.com/YouTube Follow us on twitter: @saab U.S. Media Contact: John Belanger +1 (703) 406-7905 john.belanger@saabgroup.com http://saabusa.com Follow us on Twitter: @Saab_US (https://twitter.com/Saab_US)  Saab Defense and Security USA LLC delivers advanced technology and systems to United States armed forces and other government agencies. Headquartered in Ashburn, Virginia, the company has business units and local employees in four states. Saab Defense and Security USA is a wholly owned subsidiary of the Saab Group. Saab Group serves the global market with world-leading products, services and solutions within military defence and civil security. Saab has operations and employees on all continents around the world. Through innovative, collaborative and pragmatic thinking, Saab develops, adopts and improves new technology to meet customers’ changing needs.

NetEnt plays their ace card and unleashes spectacular Motörhead slot

Guns N’ Roses and Jimi Hendrix are already wowing NetEnt’s customers and their players with their high quality game play, breathtaking design and iconic soundtracks. Now, players will be able to spin the reels to the unforgettable sounds of Phil Campbell, Mikkey Dee and Ian ‘Lemmy’ Kilimister too. From Ace of Spades to Overkill, the spine-chilling slot includes some of the band’s world famous tunes, with one of their best – Bomber – lending its name to a unique feature on the game. The five-reel, 76-line video slot also ramps up the action with free spins and wild substitution, as well as a Mystery Reel feature. Simon Hammon, Chief Product Officer of NetEnt, comments: “The NetEnt Rocks tour has rewritten the rules for branded games, with Guns N’ Roses and Jimi Hendrix exploding onto centre stage this year. Now, our customers can crank up the volume once more with the launch of our slot based on the iconic gaming song Ace of Spades, which we’re sure will capture player’s imagination yet again.” View Game Demo (https://youtu.be/kYYf4tWu8ho) For additional information please contact:Simon Hammon, Chief Product Officer NetEnt, Phone +356 2276 8145simon.hammon@netent.comMarianne Eklund, PR Manager NetEnt, Phone +46 760 024 808marianne.eklund@netent.com    About NetEnt NetEnt AB (publ) is a leading digital entertainment company, providing premium gaming solutions to the world’s most successful online casino operators. Since its inception in 1996, NetEnt has been a true pioneer in driving the market with thrilling games powered by their cutting-edge platform. With innovation at its core, NetEnt is committed to helping customers stay ahead of the competition. NetEnt is listed on Nasdaq Stockholm (NET-B), employs 750 people and has offices in Stockholm, Malta, Kiev, Gothenburg and Gibraltar. www.netent.com 

Summer 2017: Finnair opens new routes to San Francisco and Alicante

In line with its growth strategy, Finnair has today announced that it will open a new seasonal route from Helsinki to San Francisco in June 2017. The airline will operate three weekly flights between both cities from June 1 to September 30. The flights will be operated on Tuesdays, Thursdays and Sundays. Thanks to Helsinki’s geographical location, Finnair’s new northern route to San Francisco will offer competitive travel times for customers from Scandinavia, the Baltics, Russia as well as from many European cities. San Francisco will be Finnair's fourth US destination, along with New York, Chicago and Miami. The new San Francisco flight will be operated within the Atlantic joint business between Finnair, American Airlines, British Airways and Iberia. The joint business offers customers additional flight choices, better connections and better pricing on transatlantic routes. Currently, the four airlines operate over 100 daily return flights between Europe and North America. “We are very pleased to be taking another step forward in the growth of our airline as San Francisco is an exciting new destination for all of our customers,” says Juha Järvinen, Chief Commercial Officer at Finnair. “In the same way as when Finnair flies to Asia, the northern position of our Helsinki hub will also present a quick alternative for our connecting European customers flying to North America’s West Coast.” Finnair will also add capacity to Spain, by opening a new route to Alicante with up to four weekly flights between March 26 and October 27. In addition, Finnair will also increase its flights to Malaga with two additional weekly flights between June and July, increasing frequencies to a total of eleven weekly flights. Last month, Finnair also announced new routes to Ibiza and Menorca for the summer 2017 season. The new flights are available for sale on www.finnair.com as of today.

2-star Michelin head chef joins Brioche Burger to take restaurant to the next level

London based Brioche Burger has already built up an impressive reputation for serving delicious burgers and juicy steaks but is taking the restaurant to the next level with a new branch and appointment. Executive Chef Florent Fabulas, who has worked in some of the world’s finest Michelin star restaurants, will be joining the Brioche Burger team as the business opens its second branch in the hip London town of Walthamstow. The Brioche Burger menu already contains delights such as the Bangkok Dangerous, a fiery burger for those that love some extra heat, and the Fresh Prince, the restaurant’s very own take on the famous Philly Cheese Steak. With Fabulas joining the business and bringing his expertise to the table, customers can expect to enjoy even more unique creations that takes gastronomy to new heights. New menu items will be available from mid-October and include an Alaskan tempura cod burger and a super food salad that’s the perfect accompaniment to the other tempting dishes on offer.   The tasty offerings aren’t limited to main courses either, guests to Brioche Burger can sample a range of delightful milkshakes and mocktails as they enjoy their meal and follow up with some indulgent dessert. Farhad Chowdhury, Managing Director of Brioche Burger, said, “Fabulas will provide unsurpassed expertise, skill and know-how that will allow the restaurants to flourish. His culinary prowess will unlock all the delights of our carefully sourced ingredients. We are delighted that this has come together now and coincides with the opening of our new Walthamstow branch. Customers to both of our restaurants can expect outstanding food that is both familiar and exciting giving their taste buds are true treat.” The initial Brioche Burger restaurant is located in the East Shopping Centre, London, while the second branch will open its doors in October in the happening Walthamstow area. The new appointment of Fabulas and second branch of the restaurant forms part of Brioche Burger’s plan to become a leading burger and steak house that delivers on taste, atmosphere and innovation. To find out more visit http://www.briocheburger.com/.

SenzaGen signs its first distribution agreement with British XCellR8, a leader in animal-free testing

-       This agreement is important for us, not only because we now see that our business model works, we also see that there is an increased interest in our technology and we get access to a new market with a well-established and highly competent and renowned partner. XCellR8 is one of the industry's foremost ambassadors of non-animal tests, says Anki Malmborg Hager, CEO of SenzaGen. XCellR8 was established in 2008 with a mission to replace animal testing with methods that are both scientifically advanced and ethically sound. The company works with a number of leading global cosmetic companies and their ingredient suppliers, and has become the “go-to” laboratory for in vitro testing expertise for both product safety and efficacy / claim support. -       By working with GARD we take a step into the future. With the use of genomics based testing we are moving towards safer and better tests, and ultimately more reliable consumer products without the need for animal testing, says Dr Carol Treasure, CEO of XCellR8 About XCellR8XcellR8 offers animal-free testing for companies with products on the cosmetic, personal care and household product market and their ingredients suppliers. The company helps customers develop safe and innovative new products, to follow the law, and to choose non-animal test methods that are both scientifically advanced and ethical. XCellR8 's British laboratory is accredited according to GLP standard (Good Laboratory Practice), which means that the company can offer their customers test results that can be used according to regulatory requirements to prove product safety.  XCellR8 are proactive and contributing to the global commitment to replace animal testing through research and education programs.  About GARDBy analyzing 200 and 389 markers, depending on the test, GARD generates massive amounts of data and delivers results with 90 % prediction accuracy. This can be compared to the gold standard, animal tests in mice, that provides 72 % prediction. SenzaGen’s test also has the ability to measure potency (strength) of a substance and can thus determine the degree to which a substance is an allergen. About SenzaGenSenzaGen provides dermal and respiratory in vitro testing for the cosmetic, chemical and pharmaceutical industries replacing the need for animal testing. The company's unique test, GARD, is based on research from the Department of Immunotechnology at Lund University. SenzaGen is based at Medicon Village in Lund, Sweden.

Unibet Group announces share repurchase

The authority received on 17 May 2016 was regarding the buy back of a maximum number of 23,011,704 GBP 0.000625 Ordinary Shares/SDR´s in the Company. Acquisitions can be made as of 22 September 2016 until next year’s Annual General Meeting. However no acquisitions will be made during a 30-day period prior to the publication of quarterly results. Acquisitions of shares/SDRs may only take place on Nasdaq Stockholm at a price within the at each time prevailing price interval, being the interval between the highest buying price and the lowest selling price. Notification of any purchases will continuously be made to the Nasdaq Stockholm. The objective of the buyback is to achieve added value for the Company´s shareholders and to give the Board increased flexibility with the Company´s capital structure. Following repurchase the intention of the Board is to either cancel, use as consideration for an acquisition or issue to employees under a Share Incentive programme. Once repurchased under the Maltese Companies Act further shareholder approval will be required if the shares are to be cancelled. If used in connection with an acquisition, the intention would be to issue the shares/SDR´s as consideration, and not to sell them first. The total number of issued shares/SDRs in Unibet Group is 230,126,200 of which 381,144 shares/SDRs are held by the Company as a result of share buy back programmes in 2007 and 2011. Board of Directors Unibet Group plc 

Major League Baseball Players Alumni Association Brings Legends for Youth Baseball Clinic to Jacksonville, FL

Colorado Springs, Colo. – Local youth will have an opportunity to play with their big league heroes at the Major League Baseball Players Alumni Association (MLBPAA) Legends for Youth baseball clinic series on Saturday, September 24th, 2016. In partnership with the Patriot Rail Company (http://www.patriotrail.com/), the free clinic features current and former Major League Baseball players who will teach baseball skills, drills and life lessons for approximately 200 local youth.   Players attending* include Hall of Famer and 1971 Cy Young Award winner Fergie Jenkins, World Series Champion and two-time All-Star Willie Wilson, as well as Travis Baptist, Joseph Boever, Curtis Leskanic, Joe McKeon, Rick Reichardt, Desi Relaford, and Billy Wynne. These nine players combine for 91 seasons, 5032 games and 3948 hits in Major League Baseball.   The clinic will take place at James P. Small Memorial Stadium, running from 9:00 a.m. to 11:00 a.m., located at 1701 Myrtle Avenue N, Jacksonville, FL 32209. Alumni players will train at stations including pitching, catching, base running and life skills. Registration will begin at 8:30 a.m. and the morning will conclude with an autograph session and baseball giveaways for children in attendance.   Registration is closed to the public at this time.   For more information regarding the clinic, please contact Nikki Warner, Director of Communications, at (719) 477-1870, ext. 105 or visit www.baseballalumni.com. *Clinicians subject to change.   About The Major League Baseball Players Alumni Association (MLBPAA) MLBPAA was founded in 1982 with the mission of promoting baseball, raising money for charity and protecting the dignity of the game through its Alumni players. The MLBPAA is headquartered in Colorado Springs, CO with a membership of more than 7,600, of which approximately 5,600 are Alumni and active players. Alumni players find the MLBPAA to be a vital tool to become involved in charity and community philanthropy. Follow @MLBPAA for Twitter updates.   About Legends for Youth Clinics MLBPAA’s Legends for Youth clinics impact more than 15,000 children each year, allowing them the unique opportunity to interact with and learn from players who have left a lasting impact on the game of baseball. The MLBPAA has reached children across America and internationally in Australia, Canada, Curaçao, the Dominican Republic, Germany, Italy, Nicaragua, the United Kingdom and Venezuela, through the Legends for Youth clinic series. To donate to this program, visit baseballalumni.com/donate (http://www.baseballalumni.com/donate). The official hashtag of the Legends for Youth clinic series is #LFYClinic. ###

Advantech announces Hans-Peter Nüdling as new Associate Vice President Embedded Europe

Munich , September 22nd, 2016. Advantech is pursuing further in its growth ambitions within Europe by appointing Hans-Peter Nüdling as the new Associate Vice President Embedded Europe. Rejoining Advantech after 4 years of absence in September 2016, Nüdling will be managing the European Embedded team adding over 25 years of General Management, Entrepreneurship and Change Management experience to the organization.   Nüdling will be responsible for Sales, Marketing, PM, BDM, FAE, Technical Center and HR across all European territories. His extensive knowledge and experience of working in Asia and USA as an Expatriate significantly reflects major benefits to Advantech in developing the business through combining various cultures. Nüdling, always strives for profitable growth and has professional expertise in direct and channel sales, business development and operational excellence. He will be providing solid best-practice processes and optimizing interfaces to Advantech Headquarters in Taiwan which will enhance the growth strategies.   “Most importantly, we will define a vertical strategy per target market in Europe by optimizing our Go to Market approach” says Hans-Peter (HP) Nüdling. “I am very excited to re-join Advantech as the European head for our embedded business. I am convinced that we will further strengthen the relationships with our partners and customers. I will focus on major market segments, on module, system and solution level, developing efforts within Advantech and in cooperation with Eco-partners” Nüdling, who holds a diploma in Electronics Engineering (BA), has served the last eight years as a CEO of two technology businesses in electronics and medical applications focusing on entrepreneurship, scalability, change management and successful M&A processes. Additionally, Nüdling has held several different senior management positions throughout Europe, Asia and the United States. 

Elocta® obtains national reimbursement in Spain, now available in the five largest markets in the EU

Swedish Orphan Biovitrum AB (publ) (Sobi™) (http://www.sobi.com/) today announces that the company’s product Elocta® (efmoroctocog alfa), a recombinant human factor VIII Fc-fusion protein with an extended half-life for the treatment of haemophilia A, has received national reimbursement approval in Spain. Elocta is already available in the UK, France, Italy, Germany, Sweden, Denmark, Norway, Switzerland, the Netherlands, Slovenia and the Republic of Ireland. “This approval is an important reimbursement milestone for Elocta, representing the last of the five largest markets in the EU. Our focus is to continue our work to ensure timely access to Elocta for people living with haemophilia A in these countries and in the rest of the Sobi territory”, said Geoffrey McDonough CEO and President at Sobi. ------------ About Haemophilia AHaemophilia is a rare, genetic disorder in which the ability of a person's blood to clot is impaired. Haemophilia A occurs in about one in 5,000 male births annually, and more rarely in females.   People with haemophilia A experience prolonged bleeding episodes that can cause pain, irreversible joint damage and life-threatening haemorrhages. Prophylactic infusions of factor VIII can temporarily replace the missing clotting factors that are needed to control bleeding and prevent new bleeding episodes.[i] (http://teamsites.sobi.com/s/corporate-communications/Shared%20Documents/Press%20releases/042_Elocta%20reimbursement%20Spain/042e_Elocta%20reimbursed%20in%20Spain_final.docx#_edn1) The World Federation of Hemophilia recommends prophylaxis as the optimal therapy as it can prevent bleedings and joint destruction.[ii] (http://teamsites.sobi.com/s/corporate-communications/Shared%20Documents/Press%20releases/042_Elocta%20reimbursement%20Spain/042e_Elocta%20reimbursed%20in%20Spain_final.docx#_edn2) About Elocta®/Eloctate®Elocta (efmoroctocog alfa), the first recombinant clotting factor VIII therapy that offers an extended half-life in the body, is approved in the European Union, Switzerland, Iceland, Liechtenstein and Norway, as well as the United States, Canada, Australia, New Zealand, Brazil, Taiwan and Japan (as Eloctate). It was developed for haemophilia A by fusing factor VIII to the Fc portion of immunoglobulin G subclass 1, or IgG1 (a protein commonly found in the body). This enables Elocta to use a naturally occurring pathway to prolong the time the therapy remains in the body. While Fc fusion technology has been used for more than 15 years, Sobi and Biogen are the first companies to utilise it in the treatment of haemophilia. As with any factor replacement therapy, development of inhibitors may occur following administration of Elocta/Eloctate. About Sobi™Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi’s mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. Sobi also markets a portfolio of specialty and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 385 M) and about 700 employees. The share (STO: SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com. About the Sobi and Biogen Collaboration Sobi and Biogen collaborate on the development and commercialisation of the haemophilia products Elocta and Alprolix. Sobi has final development and commercialisation rights in the Sobi territory (essentially Europe, North Africa, Russia and most Middle Eastern markets). Biogen has manufacturing responsibility for Eloctate and Alprolix and has final development and commercialisation rights in North America and all other regions in the world excluding the Sobi territory. For more information please contact Media relations    Investor relationsLinda Holmström, Jörgen Winroth, Vice President, Head of InvestorExternal RelationsCommunications Manager                          T: + 46 708 73 40 95, + T: +1 347-224-0819, +1 212-579-0506, +46 8 69746 8 697 31 213574                        linda.holmstrom@sobi.com j (jorgen.winroth@sobi.com)orgen.winroth@sobi.com  ---------------------------------------------------------------------- [i] (http://teamsites.sobi.com/s/corporate-communications/Shared%20Documents/Press%20releases/042_Elocta%20reimbursement%20Spain/042e_Elocta%20reimbursed%20in%20Spain_final.docx#_ednref1) World Federation of Hemophilia. About Bleeding Disorders – Frequently Asked Questions. Available at: http://www.wfh.org/en/page.aspx?pid=637#Difference_A_B. Accessed on: June 17, 2016. [ii] (http://teamsites.sobi.com/s/corporate-communications/Shared%20Documents/Press%20releases/042_Elocta%20reimbursement%20Spain/042e_Elocta%20reimbursed%20in%20Spain_final.docx#_ednref2) Guideline for the management of hemophilia, World Federation of Hemophilia, 2nd edition, http://www1.wfh.org/publication/files/pdf-1472.pdf. Accessed December 2015 (http://www1.wfh.org/publication/files/pdf-1472.pdf.%20Accessed%20December%202015) 

Q-FREE – CONTEMPLATED PRIVATE PLACEMENT

Trondheim, Norway, 23 September 2016 The Board of Directors of Q-Free ASA (the “Company”) is contemplating raising new equity and has retained ABG Sundal Collier as manager to advise on and effect a private placement of new shares directed towards Norwegian and international institutional or professional investors ("Private Placement"). The order price will be determined through an accelerated book-building process. The increase in the share capital, if the Private Placement is completed, will be carried out according to the authorization given by the general meeting on 19 September 2016 and the maximum number of shares to be issued in the Private Placement is 17,844,689 new shares. The minimum application and allocation amount will be the NOK equivalent of EUR 100,000.  The book-building period will commence today (23 September 2016) at 09:00 CET and closes on 28 September at 16:30 CET. The Board of Q-Free and ABG Sundal Collier may, however, at any time resolve to shorten or extend the book-building period at their own discretion. The net proceeds from the Private Placement are intended to be used to strengthen the Company's balance sheet and liquidity position. This will also provide a good basis for further growth for the Company. Completion of the Private Placement is inter alia subject to necessary corporate resolutions. The Company has submitted a draft prospectus for review by the Financial Supervisory Authority of Norway which is currently expected to be approved on or about 7 October 2016.  This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. For further information, please contact: President & CEO, Håkon Volldal: +47 977 19 973 Chairman of the Board: Charlotte Brogren Karlberg: +46 70 593 56 46 CFO, Roar Østbø: +47 932 45 175 ABG Sundal Collier: +47 22 01 60 00 About Q-Free Q-Free is a leading global supplier of ITS (Intelligent Transportation Systems) products and solutions. The company has approximately 470 employees, offices in 20 countries, and presence on all continents. Headquartered in Trondheim, Norway, Q-Free is listed on the Oslo Stock Exchange. www.q-free.com Twitter: @Q-FreeASA IMPORTANT INFORMATIONThis communication may not be published, distributed or transmitted in the United States, Canada, Australia, Singapore, Thailand, United Arab Emirates or Japan. These materials do not constitute an offer of securities for sale or a solicitation of an offer to purchase securities of the Company in the United States, Norway or any other jurisdiction. The securities of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"). The securities of the Company have not been, and will not be, registered under the U.S. Securities Act. Any sale in the United States of the securities mentioned in this communication will be made solely to "qualified institutional buyers" as defined in Rule 144A under the U.S. Securities Act. No public offering of the securities will be made in the United States. The distribution of this announcement and other information in connection with the Private Placement may be restricted by law in certain jurisdictions. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions.

Safety Review Committee supports dose escalation with Betalutin® in Lymrit 37-01 trial pending safety data from cohort receiving higher pre-dosing

Oslo, Norway, 23 September 2016Nordic Nanovector ASA (OSE: NANO) announces that the independent Safety Review Committee (SRC) for the ongoing Lymrit 37-01 clinical trial of Betalutin® in follicular lymphoma (FL) has given its support to the continuation of the trial potentially at a higher dose of Betalutin® and increased pre-dosing with lilotomab, as soon as safety data from Arm 4 of the same study become available. FL is one of the most prevalent forms of non-Hodgkin lymphoma (NHL).Lymrit 37-01 is a Phase 1/2 open label, single injection dose-ascending study investigating different dose levels of Betalutin® and different pre-dosing regimens in patients with relapsed NHL with the aim of identifying an optimal dose regimen to take into the Phase 2 PARADIGME study.After a planned review of  the interim safety data from the Phase 1 and 2 parts of Arm 1  of Lymrit 37-01, based on 15 patients with relapsed/refractory FL treated with 15 MBq/kg Betalutin® and pre-dosed with 40 mg lilotomab*, the SRC concluded the following:•    The regimen of 15 MBq/kg Betalutin® administered after pre-dosing with 40 mg lilotomab is safe and the safety profile observed to date supports a possible dose escalation of Betalutin®•    The efficacy profile is promising compared to other candidates in development, particularly with regard to complete responses•    The limited safety data available to date from the first cohort of three patients in Arm 4 (receiving 15 MBq/kg Betalutin® and pre-dosed with 100mg/m2 lilotomab**) is encouraging and appears to show that an increase in pre-dosing with lilotomab improves the safety profile of Betalutin®•    Safety and dosimetry data from Arm 4 should confirm if and to what level the doses of Betalutin® and lilotomab in Phase 2 can be increased to further improve the risk/benefit profile seen so far.The company does not expect any impact to previously communicated timelines, neither for the dose definition date (Q1 2017) nor the planned pivotal PARADIGME trial, which is scheduled to start in 2H 2017.Luigi Costa, Nordic Nanovector CEO, commented: “We are pleased with the conclusions of the SRC meeting, which provide us with further confidence that we are closing in on the optimal dose regimen.”    *Lilotomab is a murine anti-CD37 antibody, previously referred to as HH1. The way the dose of lilotomab is referred to has been changed (from 50 mg/patient to 40mg/patient) following further characterisation of lilotomab, which has determined the actual absorbance factor of lilotomab reference standard (1.74 vs. the previous estimate of 1.4). The absorbance factor is used to measure the concentration of lilotomab drug product.**The change in dose units for lilotomab from mg to mg/m2 is because a more accurate way of calculating the administered concentration of antibody is now being applied, as described in previous footnote.For further information, please contact:IR enquiries:Luigi Costa, Chief Executive OfficerCell: +41 79 124 8601Tone Kvåle, Chief Financial OfficerCell: +47 91 51 95 76Email: ir@nordicnanovector.comMedia enquiries:Mark Swallow/David Dible (Citigate Dewe Rogerson)Tel: +44 207 282 2948/+44 207 282 2949Email: nordicnanovector@citigatedr.co.ukAbout Nordic Nanovector:Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018.Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab (previously referred to as HH1), conjugated to a low intensity radionuclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulatory submission anticipated in 1H 2019.Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat multiple selected cancer indications.Further information about the Company can be found at www.nordicnanovector.comThis information is subject to the disclose requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. 

RayStation innovations and RayCare on show at ASTRO 2016

During September 25–28, RaySearch will be exhibiting at the ASTRO 2016 Annual Meeting in Boston, US. The company will demonstrate new features in the upcoming release of its proprietary treatment planning system, RayStation®. In addition, RaySearch will demonstrate its oncology information system, RayCare®, which is under development and due to be launched in the second half of 2017. Attendees are welcome to visit RaySearch at booth #12012, and demonstrations can be booked now at www.raysearchlabs.com. New features in RayStation 6The upcoming release of RayStation will include some exciting new functionality. One of the highlights is treatment planning* for the Accuray TomoTherapy® and Radixact™ Systems. Demonstrations will be available at both the RaySearch and Accuray booths. RayStation 6 will also include MR-based planning and new developments for proton therapy planning, including Monte Carlo dose calculation*, which will all be on show. Automated planning and Plan ExplorerRayStation has extensive automated planning features that help optimize workflows and create new treatment possibilities. Plan Explorer, for example, makes it possible to automatically generate a large number of high-quality treatment plan alternatives, saving valuable time and giving the clinician a wide range of options to consider. Adaptive therapy is now!RayStation is designed to make adaptive therapy easy to implement and perform in clinical practice. At the RaySearch booth, attendees can discover how automation features and smart tools in the fully integrated dose tracking and adaptive planning modules make it straightforward to get started. The next-generation OISRayCare has been developed from the ground up by RaySearch to support the complex logistical challenges in modern, large-scale radiation therapy centers. RayCare integrates the high-performance radiation therapy algorithms available in RayStation and adds advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy. 

Multifaceted genetic impact of training

Regular endurance training is very beneficial to health and wellbeing, and can be used to prevent cardiovascular disease, diabetes, obesity and other such conditions. However, just how this works on a molecular level is not fully known.  Researchers at Karolinska Institutet have now analyzed RNA, the molecular copies of the DNA-sequence, in muscle tissue before and after endurance training. They found approximately 3400 RNA variants, associated with 2600 genes, that changed in response to training. One implication of the study is that training can induce the same gene to increase the production of one RNA variant and reduce that of another. According to the researchers, this can mean that genes can change function as a result of exercise and, for example, start to promote the production of certain protein variants over others. “It has not been previously shown that training changes the expression of genes in this particular way. The study also provides new basic information about how the body adapts to regular endurance training and what role many of our genes play in the adaptation,” says Dr Maléne Lindholm at Karolinska Institutet’s Department of Physiology and Pharmacology. The study began with an exercise programme for 23 individuals that involved working one leg but not the other. Muscle samples were taken before and after the training period. After a nine months rest period, they then exercised both legs in the same way as in the initial period of exercise, with muscle samples taken from both legs. “We were looking for any residual effects of previous training, a kind of muscle memory as it were, and trying to find out if this could influence the response to repeated training.” The changed genetic activity in the previously trained leg was no longer present when exercise resumed. However, the repeated response to training was somewhat different in the trained and previously untrained legs in the second training period, which suggests that the exercise could have left other lasting impacts. According to Dr Lindholm, the study is important above all for the fundamental understanding of how muscles operate and how we adapt to endurance training. “The results can also contribute to the future optimisation of training effects in different individuals,” she says. “In the long run, it is conceivably of some significance to the possibility of preventing cardiovascular disease and the development of new, more precise drugs for people who, for whatever reason, are unable to exercise.” The study was financed by the Swedish National Centre for Research in Sports, Karolinska Institutet and the Knut and Alice Wallenberg Foundation Publication: ”The impact of Endurance Training on Human Skeletal Muscle Memory, Global Isoform Expression and Novel Transcripts” Maléne Lindholm, Stefania Giacomello, Beata Werne Solnestam, Helene Fischer, Mikael Huss, Sanela Kjellqvist, Carl Johan Sundberg. PLOS Genetics, published online 22 September, 2016, doi: PGENETICS-D-16-01025 If you have any questions, please contact: Maléne Lindholm, PhD, Department of Physiology and Pharmacology, Karolinska Institutet Tel: +46 70 749 49 52 E-mail: Malene.Lindholm@ki.se

The Switch, a Yaskawa company, to acquire Wärtsilä Drives’ products

PRESS RELEASE: For release on September 23, 2016(For German and Norwegian versions see attached) The Switch, a Yaskawa company, to acquire Wärtsilä Drives’ products, R&D and manufacturing to strengthen its core advanced electrical drive train offering.  Finland, September 23, 2016 – The Switch, a technology specialist of advanced drive trains, announced its acquisition of Wärtsilä’s marine drives business that encompasses specialized megawatt-class power drives targeting marine applications. The Yaskawa-backed investment gives The Switch a stronger foothold in its growing marine business area. Together, The Switch and the Norway-based marine drives business aim to benefit from a number of inherent added-value synergies, including a stronger machine and drive package offering, a broader product range and a wider market access.  As part of the deal, The Switch will gain part of Wärtsilä’s Electrical & Automation (E&A) business line’s test center and the manufacturing facilities in Stord, Norway, that are associated with its marine drives. The Switch will then become a supply chain partner of Wärtsilä for marine drives while also being able to open up the product offering to other customers. The business transition from Wärtsilä to The Switch is due for completion once the operations have been transferred to The Switch. Stronger core offering The Switch investment in the marine drives business enables both companies to fully focus on developing their core competences and creating drive train solutions with better synergy together. Wärtsilä aims to focus on systems, whereas The Switch strives to be the best in providing drive train components to future proof vessels. The specialized marine R&D teams of the synergetic group will collaborate closely, enabling The Switch and Yaskawa to bring additional technical resources to ongoing and future solutions. Additionally, the two will be able to take advantage of building on each other’s solid technical knowledge. Broader product range This acquisition gives The Switch an opportunity to enhance its offering of world-class products since Wärtsilä’s drive offering is optimized for marine applications. This allows The Switch to broaden its marine business, an area which is taking off with the growing acceptance of the company’s permanent magnet technology. The power drive products are used as proven elements within Wärtsilä’s systems that have already passed various approval requirements and are used in applications ranging from propulsion to drilling. There are currently hundreds of ships sailing with Wärtsilä marine drives. This makes them attractive to other marine customers who are seeking to reduce risk while upgrading to more advanced drive train solutions and hybrid systems. “The Wärtsilä drive products are specially made without compromise for marine applications. These products are ready for integration with various other systems because of their superior communication features, including de facto industry standard interfaces and remote management possibilities. It is also possible to separate the logistics for cabinets and power modules by shipping them later to avoid damages during the long installation times at shipyards,” says Jukka-Pekka Mäkinen, President and CEO of The Switch.   Wider market access As part of The Switch, the power drives unit will be able to explore new audiences to expand its business. It will also be better positioned to serve customers thanks to The Switch’s extensive international sales and marketing network as well as to offer customers strong after-sales support. Thanks to Yaskawa’s involvement in the investment, the mother company will demonstrate its continued support and interest to ensure that The Switch becomes a major player in its chosen area. For the marine segment, The Switch works closely with Yaskawa as an integrated team and thereby is able to offer this wider product range globally. “At the moment, the oil and gas market is in a slump. Yet, we are taking a longer perspective in our views of this market. Now is good time to engineer future-proof solutions for marine. Once the market picks up, we’ll be ready to implement them,” says Jukka-Pekka Mäkinen. About The Switch The Switch, a Yaskawa company, is a pioneer in advanced drive train technology. The company has an installed base of over 11 GW of megawatt-class permanent magnet machine and converter packages. The main focus areas are wind, marine and special industrial solutions. The company’s innovative drive trains make an impact on profitable power generation and energy use, with the ultimate goal of lowering the cost of energy and operations. The Switch is headquartered in Helsinki, Finland. For more information, visit: www.theswitch.com. About Yaskawa Yaskawa Electric Corporation is a world-leading provider of core technologies focused on motion control, robotics automation, and systems engineering. Since it was founded in 1915, Yaskawa Electric has provided motor applications, advancement of industrial automation, the creation of mechatronics and cutting-edge robotics. Yaskawa today employs over 14,000 persons globally in its core divisions. The company reported net sales of EUR 3.3 billion in 2015. For more information, visit  www.yaskawa.co.jp  FOR MORE INFORMATION, PLEASE CONTACT: Lisa Kettman-Kervinen, Marketing Communication SpecialistThe Switch: Tel. +358 50 554 5044, lisa.kettman-kervinen@theswitch.com  Jukka-Pekka Mäkinen, President and CEOThe Switch: Tel. +358 40 8080 580, jukka-pekka.makinen@theswitch.com 

Stena Line to add extra North Sea freight capacity on Rotterdam to Killingholme route

The RoRo ship Caroline Russ, has been brought in to operate three times weekly from Europoort in the Netherlands and Killingholme in the UK, with the first departure from Europoort on October 31, 2016. The ship will join current RoRo ship, the Stena Scotia, on the route. The frequency will hereby increase to six departures per week in each direction. The Stena Scotia was introduced on the route September 2014 as a complement to the two freight ships, the Stena Transit and Stena Transporter on the Hoek van Holland – Killingholme route. Annika Hult, Route Manager at Stena Line North Sea says: “We have seen a strong growth in the transport market to the UK over the past several years. We introduced our freight ship the Stena Scotia in 2014 in order to accommodate growing volumes of traffic. I am very pleased to announce that we will now take the next step in the strategic development of our Rotterdam (Europoort) – Killingholme route.” “We expect trade to remain strong and want to be in the best place to service our customers and meet additional demands. Europoort continues to develop as an important freight hub for Stena Line and we are confident our customers will react positively to our expanded service”, she continues. Facts Caroline Russ Type of ship: RoRoYear of construction: 1999Length: 153 mWidth: 20.6 mMax speed: 20 knTrailers: 102Passengers: 12 Sailing Schedule Caroline Russ and Stena Scotia: By introducing a second ship the frequency is increased to daily departures (6 days a week).  +---------------------------------------+------------------------+|Killingholme – Europoort (local times) |  |+---------------------------------------+------------------------+|Departure:  |Arrival:  |+---------------------------------------+------------------------+|Monday / Friday 22:00 hrs  |Following day 12:00 hrs ||Sunday 16:30 hrs  |Following day 06:45 hrs |+---------------------------------------+------------------------+|  |  |+---------------------------------------+------------------------+|Europoort – Killingholme (local times) |  |+---------------------------------------+------------------------+|Departure:  |Arrival:  |+---------------------------------------+------------------------+|Monday / Friday 16:45 hrs   |Following day 05:00 hrs ||Sunday 14:45 hrs  |Following day 03:00 hrs |+---------------------------------------+------------------------+ For more timetable information, please visit www.stenalinefreight.com Stena Line, Gothenburg 23 September 2016

Amigo Loans guarantor agreement deemed unenforceable by court

Guarantor loan provider Amigo Loans, which markets itself as a loan option for people with bad credit, has had a recent claim against a guarantor dismissed by a district judge after it was found that the company had breached principal obligations under the Consumer Credit Act 1974, as well as other acts and regulations. This has resulted in the guarantor agreement being deemed unenforceable. Amigo Loans was seeking a guarantor, Miss Abbas, to pay debt in excess of £5,000. However, the case was dismissed and permission to appeal refused after District Judge Beck concluded that the guarantor agreement could not be enforced because there was no evidence to suggest that a copy of the borrower’s agreement was provided to the defendant, who was supported by Landlord Advice UK, before numerous requests from Miss Abbas. Initially, it is understood that Amigo Loans believed the guarantor was not entitled to the agreement due to data protection laws. The evidence also indicates that Amigo Loans failed to serve a cancellation notice on the guarantor. Sasha Charles, Housing Lawyer and Director of Landlord Advice UK, said, “The case highlights the poor conduct of Amigo Loans and their failure to protect consumers as required. The conduct of Amigo Loans puts all of their guarantors at an unfair disadvantage due to non-compliance. The case should also serve as a warning for landlords and agents, who commonly use unenforceable guarantor agreements and may not be able to claim back their debts should their tenants default on payments.” The Amigo Loans Limited v Abbas trial took place at Reigate Country court on 14th September 2016. Amigo Loans did not attend the court but was represented and submitted a witness statement as evidence. The district judge advised that the evidence was heavily disputed on a point of law before adjourning the hearing so the claimant’s representative could take instructions. To find out about Landlord Advice UK visit http://www.landlordadvice.co.uk/.

Jackpot joy as €5million drops on NetEnt’s Mega Fortune slot

The Norwegian man, playing on the Betsson.com website, is the second multi-millionaire to be created playing Mega Fortune this year, following a €2.7m windfall in the UK in January. Initially the man, in his 20s, thought he’d won 45,000 kroner (€4,900), before realising he’d won the life-changing amount. He said: “I was playing NetEnt’s Mega Fortune game a little before bed, and then suddenly the jackpot hit. I was unsure at first if it was true, but it has gradually dawned on me how much I’ve won. I’ll build a house with the money, but otherwise want to just carry on as normal.” Simon Hammon, Chief Product Officer at NetEnt, said: “Mega Fortune continues to be one of NetEnt’s best performing and most played games, and we’re over the moon that another jackpot has dropped. We’re looking forward to even more players enjoying the great gameplay and features in the future, and I’m sure it won’t be too long before the slot changes another life for the good.” For additional information please contact: Simon Hammon, Chief Product Officer NetEnt, Phone +356 2276 8145simon.hammon@netent.comMarianne Eklund, PR Manager, Phone +46 760 024 808marianne.eklund@netent.com About NetEnt  NetEnt AB (publ), is a leading digital entertainment company, providing premium gaming solutions to the world’s most successful online casino operators. Since its inception in 1996, NetEnt has been a true pioneer in driving the market with thrilling games powered by a cutting-edge platform. NetEnt is committed to helping customers stay ahead of the competition, is listed on NASDAQ OMX Stockholm (NET–B) and employs 800 people in Stockholm, Malta, Kiev, Gothenburg, Krakow, New Jersey and Gibraltar. www.netent.com (http://file:///C:/Users/Admin/AppData/Local/Microsoft/Windows/Temporary%20Internet%20Files/Content.Outlook/P2W12YLV/www.netent.com)